Temozolomide derivative with poly ADP ribose polymerase inhibitory activity and preparation method and application thereof
By preparing temozolomide derivatives with PARP1 inhibitory activity, the problem of temozolomide resistance was solved, the therapeutic effect of glioblastoma was improved, and it is suitable for the treatment of a variety of tumors.
Patent Information
- Application Number
- CN202411437894.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2026-04-17
AI Technical Summary
Temozolomide, a current drug for treating glioblastoma, is prone to drug resistance, leading to reduced patient survival rates, and there is a lack of effective alternative drugs.
Temozolomide derivatives with PARP1 inhibitory activity were developed and prepared via a specific chemical synthesis route.
It effectively inhibits PARP1, improves the therapeutic effect of temozolomide, reduces the recurrence rate of glioblastoma, solves the problem of drug resistance, and is suitable for the treatment of a variety of tumors.
Smart Images

Figure CN121873079A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the fields of medicinal chemistry and pharmacotherapeutic science, and specifically relates to temozolomide derivatives with poly(ADP-ribose polymerase 1) (PARP1) inhibitory activity, their preparation methods and uses, and pharmaceutical compositions containing the temozolomide derivatives. Background Technology
[0002] Glioblastoma (GBM) is a common primary brain tumor caused by the abnormal growth of astrocytes. Glioblastoma is classified as a grade IV glioma, the most malignant of all astrocyte tumors, and its pathogenesis remains unclear. Glioblastoma grows rapidly, has a poor prognosis, and a median survival of less than two years. This disease causes severe suffering for patients and places a significant burden on families and society.
[0003] Currently, the treatment of glioblastoma mainly involves a combination of surgery, radiotherapy, chemotherapy, and tumor-treating fields (TTFields) therapy. Postoperative radiotherapy combined with temozolomide concurrently with adjuvant temozolomide chemotherapy is the standard treatment regimen for newly diagnosed GBM in adults.
[0004] Temozolomide (TMZ) is a monofunctional small-molecule DNA alkylating agent that can cross the blood-brain barrier, belonging to the imidazotetrazine class of compounds. Since its approval and marketing over the past 20 years, TMZ has been a first-line treatment for GBM, and currently there are no other alternative drugs. Acquired resistance to TMZ in GBM treatment is a significant challenge. It is generally believed that TMZ resistance is... 6 -Methylguanine DNA methyltransferase (O 6 The high expression of β-methyl-guanine-DNAmethytransferase (MGMT) and the loss of mismatch repair (MMR) function are the consequences. In approximately 80% of patients, relapse or transformation into advanced tumors resistant to TMZ during treatment leads to decreased patient survival. Therefore, reducing TMZ resistance in GBM patients, improving their chemosensitivity, and lowering the tumor recurrence rate are urgent problems to be solved in the clinical treatment of GBM.
[0005] Poly(ADP-ribose) polymerase (PARP) is a class of enzymes involved in DNA repair and apoptosis. The PARP1 isoform is closely related to DNA damage repair and can repair the damage caused by temozolomide to tumor cells. Multiple experiments have shown that knocking out PARP1 can improve the therapeutic effect of temozolomide. Summary of the Invention
[0006] The purpose of this invention is to provide a temozolomide derivative with poly(ADP-ribose) polymerase 1 inhibitory activity.
[0007] The objective of this invention is achieved through the following technical means:
[0008] Temozolomide derivatives or pharmaceutically acceptable salts, crystal forms, or solvates with the structure shown in Formula (I) and exhibiting polyADP-ribose polymerase 1 inhibitory activity:
[0009]
[0010] Wherein, R1 is selected from
[0011] R 2a R 2b R 2c R 2d Each amino group is independently selected from any substituted amino group. 1-8 Alkyl, amino C 1-8 Alkoxy, single or two five- or six-membered alicyclic groups with heteroatoms selected from O, S, and N, single or two five- or six-membered aromatic heterocyclic groups with heteroatoms selected from O, S, and N, bridged cyclic hydrocarbons, N-heterospirocyclic groups, N-alkyl-substituted single or two five- or six-membered alicyclic groups with heteroatoms selected from O, S, and N, and N-alkyl-substituted single or two five- or six-membered aromatic heterocyclic groups with heteroatoms selected from O, S, and N;
[0012] R 5a R 5b R 5c R 5d Each group is independently selected from hydrogen, hydroxyl, carboxyl, aldehyde, halogen, isopropyl, trifluoromethyl, methoxy, methoxycarbonyl, acetyl, cyano, and nitro.
[0013] R4 is selected from any substituted amino group C. 1-8 Alkyl, amino C 1-8 Alkoxy, single or two five- or six-membered alicyclic groups selected from O, S, and N heteroatoms, single or two five- or six-membered aromatic heterocyclic groups selected from O, S, and N heteroatoms, N-alkyl-substituted single or two five- or six-membered alicyclic groups selected from O, S, and N heteroatoms, N-alkyl-substituted single or two five- or six-membered aromatic heterocyclic groups selected from O, S, and N heteroatoms, and methylthioalkylamino;
[0014] n is 0, 1, 2, or 3;
[0015] R3 is selected from hydrogen, halogen, methyl, or halogen-substituted methyl;
[0016] But not including: R1 selected from R 2c Selected from m3 = 3, n is 1, and R3 is selected from hydrogen.
[0017] Preferably, R1 is selected from
[0018] R 2a Selected from
[0019] R 2b R 2c R 2d Selected independently m1 is an integer from 1 to 4; m2 is 1, 2, or 3; m3 is 1, 2, or 3;
[0020] R4 is selected from m4 is selected from 1, 2, or 3;
[0021] n is 1 or 2;
[0022] R3 is selected from hydrogen and Cl;
[0023] But not including: R1 selected from R 2c Selected from m3 = 3, n is 1, and R3 is selected from hydrogen.
[0024] Further preferably, R1 is selected from
[0025] R 2a Selected from
[0026] R 2b R 2c Selected independently m2 is 1, 2, or 3; m3 is 1, 2, or 3;
[0027] R 2d Selected from m1 is 2, 3, or 4; m2 is 1, 2, or 3; m3 is 1, 2, or 3.
[0028] R4 is selected from m4 is selected from 1, 2, or 3;
[0029] n is 1 or 2;
[0030] R3 is selected from hydrogen and Cl;
[0031] But not including: R1 selected from R 2c Selected from m3 = 3, n is 1, and R3 is selected from hydrogen.
[0032] More preferably, R1 is selected from
[0033] R 2a Selected from
[0034] R 2b Selected from
[0035] R 2d Selected from m1 is 2, 3, or 4; m2 is 1, 2, or 3; m3 is 2;
[0036] n is 1 or 2;
[0037] R3 is selected from hydrogen and Cl.
[0038] As one of the technical solutions of the present invention, a temozolomide derivative or a pharmaceutically acceptable salt, crystal form, or solvate having polyADP-ribose polymerase 1 inhibitory activity, as shown in general formula (II), is provided.
[0039]
[0040] Among them, R 5a R 2a As previously stated, n and R3.
[0041] As one of the technical solutions of the present invention, a temozolomide derivative or a pharmaceutically acceptable salt, crystal form, or solvate having polyADP-ribose polymerase 1 inhibitory activity, as shown in general formula (Ⅲ), is provided.
[0042]
[0043] R3 and R4 are as described above.
[0044] As one of the technical solutions of the present invention, a temozolomide derivative or a pharmaceutically acceptable salt, crystal form, or solvate having polyADP-ribose polymerase 1 inhibitory activity, as shown in general formula (Ⅳ), is provided.
[0045]
[0046] Wherein, n and R3 are as described above.
[0047] As one of the technical solutions of the present invention, a temozolomide derivative or a pharmaceutically acceptable salt, crystal form, or solvate having polyADP-ribose polymerase 1 inhibitory activity, as shown in general formula (V), is provided.
[0048]
[0049] Among them, R 5c R 5d R 2d As previously stated, n and R3.
[0050]
[0051] Among them, R 5b R 2a As previously stated, n and R3.
[0052]
[0053] Among them, R 2c As previously stated, n and R3.
[0054] Temozolomide derivatives or pharmaceutically acceptable salts, crystal forms, or solvates with the following structures and exhibiting polyADP-ribose polymerase 1 inhibitory activity:
[0055]
[0056]
[0057]
[0058] As the most preferred technical solution of the present invention, a temozolomide derivative or a pharmaceutically acceptable salt, crystal form, or solvate having polyADP-ribose polymerase 1 inhibitory activity, as shown in the following formula, is provided:
[0059]
[0060] The solvates of the temozolomide derivatives include, but are not limited to, the hydrates of the temozolomide derivatives.
[0061] A second objective of this invention is to provide a method for preparing a temozolomide derivative having poly(ADP-ribose) polymerase 1 inhibitory activity.
[0062] When R1 is selected The synthetic route for temozolomide derivatives is as follows:
[0063]
[0064] Among them, R 2a R3, R5a As mentioned above;
[0065] Includes the following steps:
[0066] Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2.
[0067] Wherein, the molar ratio of compound m-1 to NaNO2 is 1:3.5 to 1:3.6; the concentration of the NaNO2 aqueous solution is 1.25 to 1.85 mol / L; and the concentrated sulfuric acid is a sulfuric acid solution with a mass fraction ≥70%, preferably a 98% sulfuric acid solution.
[0068] After the reaction is complete, the reaction solution is added to ice water, and after the solid precipitates, it is filtered and dried.
[0069] Step (ii): Using DMF as the reaction solvent, compound a-1 (2,3-diaminobenzamide) and compound a-2 react at room temperature for about 4 to 26 hours in the presence of HATU and one of DIPEA (N,N-diisopropylethylamine) or TEA (triethylamine). After the reaction is completed, the reaction solution is added to ice water, extracted with ethyl acetate and the ethyl acetate is removed under vacuum. The remaining solid is heated under reflux in acetic acid at 70 to 120°C for about 2 to 6 hours to obtain compound a-3.
[0070] The molar ratio of compound a-1 (2,3-diaminobenzamide) to compound a-2 is 1:1 to 1.2:1; the molar ratio of HATU to compound a-2 is 1:1 to 1.5:1; and the molar ratio of one of DIPEA or TEA to compound a-2 is 2:1 to 3:1.
[0071] Step (iii): Compound a-3 was reacted at room temperature for 24 h in a mixed solution of THF, MeOH and LiOH aqueous solution in a volume ratio of 10:3:2 to obtain compound a-4; wherein the concentration of LiOH aqueous solution was 5 mol / L.
[0072] After the reaction was completed, the pH of the reaction solution was adjusted to neutral under ice bath conditions with 3 mol / L HCl, the solid precipitated, and the solid was filtered under reduced pressure. The obtained solid was dried to obtain compound a-4.
[0073] Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-4 reacts with R... 2a -Boc reacts at room temperature for about 4 to 6 hours to give compound a-5;
[0074] Among them, compound a-4 and R 2a The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound a-4 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound a-4 to acid-binding agent is 1:2 to 1:3;
[0075] After the reaction was completed, the reaction solution was slowly added dropwise to ice water at a volume ratio of 1:8 to 1:10 (based on the reaction solvent). After the solid was completely precipitated, the mixture was filtered under reduced pressure. The solid was dried to obtain the crude product. The crude product was purified by normal-phase silica gel column chromatography (eluent EA:PE = 7:3 V / V) to obtain compound a-5.
[0076] Step (v): Compound a-5 is reacted at room temperature in an acidic reaction system for about 2 hours to remove the Boc protecting group, yielding compound a-6; the acidic reaction system is a 4 mol / L ethyl acetate hydrochloride solution;
[0077] Step (vi): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-6 and compound m-2 are reacted at room temperature for about 4 to 6 hours to obtain the target compound with the structure described in Formula II.
[0078] The molar ratio of compound a-6 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:3.
[0079] After the reaction was completed, the reaction solution was slowly added dropwise to ice water at a volume ratio of 1:8 to 1:10 (based on the reaction solvent). Ethyl acetate was then added for extraction. The organic phases were combined and evaporated to dryness to obtain the crude product. The crude product was purified by normal-phase silica gel column chromatography (eluent: dichloromethane:methanol = 20:1 V / V) to obtain the target compound.
[0080] R1 is selected from The synthetic route for temozolomide derivatives is as follows:
[0081]
[0082] Among them, R3, R4, and n are as described above;
[0083] Includes the following steps:
[0084] Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2.
[0085] Wherein, the molar ratio of compound m-1 to NaNO2 is 1:3.5 to 1:3.6; the concentration of the NaNO2 aqueous solution is 1.25 to 1.85 mol / L; and the concentrated sulfuric acid is a sulfuric acid solution with a mass fraction ≥70%, preferably a 98% sulfuric acid solution.
[0086] Step (ii): Using DMF as the reaction solvent, compound a-1 (2,3-diaminobenzamide) and compound a-7 are reacted at room temperature for about 4 to 6 hours in the presence of HATU and one of DIPEA (N,N-diisopropylethylamine) or TEA (triethylamine) to obtain compound a-8.
[0087] The molar ratio of compound a-1 (2,3-diaminobenzamide) to compound a-7 is 1:1 to 1.2:1; the molar ratio of HATU to compound a-7 is 1:1 to 1.5:1; and the molar ratio of one of DIPEA or TEA to compound a-7 is 2:1 to 3:1.
[0088] After the reaction was completed, the reaction solution was added to ice water, extracted with ethyl acetate and the ethyl acetate was removed under vacuum. The remaining solid was heated under reflux at 70-120℃ for about 4-6 hours in an acetic acid environment to obtain compound a-8.
[0089] Step (iii): Compound a-8 is reacted at room temperature in an acidic reaction system for about 2-4 hours to remove the Boc protecting group, yielding compound a-9; the acidic reaction system is a 4 mol / L ethyl acetate hydrochloride solution;
[0090] Step (vii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-9 and compound m-2 are reacted at room temperature for about 4 to 6 hours to obtain the standard compound with the structure shown in Formula III.
[0091] The molar ratio of compound a-9 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:3.
[0092] After the reaction was completed, the reaction solution was slowly added dropwise to ice water at a volume ratio of 1:8 to 1:10 (based on the reaction solvent). Ethyl acetate was then added for extraction. The organic phases were combined and evaporated to dryness to obtain the crude product. The crude product was purified by normal-phase silica gel column chromatography (eluent: dichloromethane:methanol = 20:1 V / V) to obtain the target compound.
[0093] R1 is selected from The synthetic route for temozolomide derivatives is as follows:
[0094]
[0095] Among them, R3 and n are as described above;
[0096] Includes the following steps:
[0097] Step (i): Compound m-1 is added to concentrated sulfuric acid, and NaNO2 aqueous solution is added under ice bath conditions. After the addition is complete, the mixture is kept in an ice bath for 45-60 min, and then reacted at room temperature for 6-12 h to obtain compound m-2. The molar ratio of compound m-1 to NaNO2 is 1:3.5 to 1:3.6. The concentration of the NaNO2 aqueous solution is 1.25-1.85 mol / L, and the concentrated sulfuric acid is a sulfuric acid solution with a mass fraction ≥70%, preferably a 98% sulfuric acid solution.
[0098] Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-1 (2,3-diaminobenzamide) reacts with compound m-2 at room temperature for about 4-6 hours. After the reaction is complete, the reaction solution is added to ice water at a volume ratio of 1:8 to 1:10 based on the reaction solvent. After extraction with ethyl acetate, the ethyl acetate is removed from the organic phase under vacuum. The solid is refluxed in acetic acid at 70-120°C for about 4-6 hours. After the reaction is complete, the solid is evaporated to dryness. The crude product is purified by normal-phase silica gel column chromatography (eluent: dichloromethane:methanol = 96:4V / V) to obtain the target compound with the structure shown in Formula IV.
[0099] The molar ratio of compound a-1 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:1.8 to 1:3.
[0100] R1 is selected from The synthetic route for temozolomide derivatives is as follows:
[0101]
[0102] Among them, R 2d R3, R 5c R 5d As mentioned above;
[0103] Includes the following steps:
[0104] Step (i): Compound m-1 is added to concentrated sulfuric acid, and NaNO2 aqueous solution is added under ice bath conditions. After the addition is complete, the mixture is kept in an ice bath for 45-60 min, and then reacted at room temperature for 6-12 h to obtain compound m-2. The molar ratio of compound m-1 to NaNO2 is 1:3.5 to 1:3.6. The concentration of the NaNO2 aqueous solution is 1.25-1.85 mol / L, and the concentrated sulfuric acid is a sulfuric acid solution with a mass fraction ≥70%, preferably a 98% sulfuric acid solution.
[0105] Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-1 reacts with R... 2d -Boc reacts at room temperature for about 4 to 6 hours to give compound b-2;
[0106] Among them, compound b-1 and R 2d The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound b-1 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound b-1 to acid-binding agent is 1:2 to 1:3;
[0107] After the reaction was completed, the reaction solution was slowly added dropwise to ice water at a volume ratio of 1:8 to 1:10 (based on the reaction solvent). Ethyl acetate was then added for extraction. The organic phases were combined, evaporated to dryness, and the crude product was purified by normal-phase silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 3:7 V / V) to obtain compound b-2.
[0108] Step (iii): Compound b-2 is reacted in ethyl acetate solution of 4 mol / L hydrochloric acid at room temperature for about 2-3 hours to remove the Boc protecting group, yielding compound b-3;
[0109] Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-3 and compound m-2 are reacted at room temperature for about 4 to 6 hours to obtain the target compound with the structure shown in Formula V.
[0110] The molar ratio of compound b-3 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:3.
[0111] After the reaction was completed, the reaction solution was added to ice water, followed by extraction with ethyl acetate. The organic phases were combined, evaporated to dryness, and the crude product was purified by normal-phase silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 95: 5V / V) to obtain the target compound.
[0112] R1 is selected from The synthetic route for temozolomide derivatives is as follows:
[0113]
[0114] Among them, R 2b R3, R 5b As mentioned above;
[0115] Includes the following steps:
[0116] Step (i): Compound m-1 is added to concentrated sulfuric acid, and NaNO2 aqueous solution is added under ice bath conditions. After the addition is complete, the mixture is kept in an ice bath for 45-60 min, and then reacted at room temperature for 6-12 h to obtain compound m-2. The molar ratio of compound m-1 to NaNO2 is 1:3.5 to 1:3.6. The concentration of the NaNO2 aqueous solution is 1.25-1.85 mol / L, and the concentrated sulfuric acid is a sulfuric acid solution with a mass fraction ≥70%, preferably a 98% sulfuric acid solution.
[0117] Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-4 reacts with R... 2b -Boc reacts at room temperature for about 4 to 6 hours to give compound b-5;
[0118] Among them, compound b-4 and R 2b The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound b-4 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound b-4 to acid-binding agent is 1:2 to 1:3;
[0119] Step (iii): Compound b-5 was reacted in ethyl acetate solution of 4 mol / L hydrochloric acid at room temperature for about 2-3 hours to remove the Boc protecting group, yielding compound b-6;
[0120] Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-6 and compound m-2 are reacted at room temperature for about 4 to 6 hours to obtain the target compound with the structure shown in Formula VI.
[0121] The molar ratio of compound b-6 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:3.
[0122] When R1 is selected The synthetic route for temozolomide derivatives is as follows:
[0123]
[0124] Among them, R 2c R3 and n are as described above;
[0125] Includes the following steps:
[0126] Step (i): Compound m-1 is added to concentrated sulfuric acid, and NaNO2 aqueous solution is added under ice bath conditions. After the addition is complete, the mixture is kept in an ice bath for 45-60 min, and then reacted at room temperature for 6-12 h to obtain compound m-2. The molar ratio of compound m-1 to NaNO2 is 1:3.5 to 1:3.6. The concentration of the NaNO2 aqueous solution is 1.25-1.85 mol / L, and the concentrated sulfuric acid is a sulfuric acid solution with a mass fraction ≥70%, preferably a 98% sulfuric acid solution.
[0127] Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-7 reacts with R... 2c -Boc reacts at room temperature for about 4 to 6 hours to give compound b-8;
[0128] Among them, compound b-7 and R 2c The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound b-7 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound b-7 to acid-binding agent is 1:2 to 1:3;
[0129] Step (iii): Compound b-8 was reacted in ethyl acetate solution of 4 mol / L hydrochloric acid at room temperature for about 2-3 hours to remove the Boc protecting group, yielding compound b-9;
[0130] Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-9 and compound m-2 are reacted at room temperature for about 4 to 6 hours to obtain the target compound with the structure shown in Formula VII.
[0131] The molar ratio of compound b-9 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:3.
[0132] The temozolomide derivative of the present invention can specifically inhibit PARP1 (polyADP-ribose polymerase 1) and has PARP1 inhibitory effect.
[0133] A third object of the present invention is to provide the use of the temozolomide derivative or pharmaceutically acceptable salt, crystal form, or solvate in the preparation of PARP1 inhibitors.
[0134] A fourth object of the present invention is to provide the use of the temozolomide derivative or pharmaceutically acceptable salt, crystal form, or solvate thereof in the preparation of medicaments for the prevention and / or treatment of tumors.
[0135] The tumors mentioned are glioblastoma, ovarian cancer, breast cancer, bladder cancer, bone cancer, stomach cancer, liver cancer, non-small cell lung cancer, melanoma, prostate cancer, and rectal cancer.
[0136] Since the temozolomide derivatives of the present invention have the activity of inhibiting the proliferation of various tumor cell lines, the temozolomide derivatives of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, solvates, and pharmaceutical compositions containing the temozolomide derivatives of the present invention as the main active ingredient can be used to treat, prevent and alleviate various diseases, including various cancers.
[0137] The fifth object of the present invention is to provide a pharmaceutical composition wherein the pharmaceutical composition comprises, in a safe and effective amount of the temozolomide derivative or a pharmaceutically acceptable salt, crystal form or solvate as the active ingredient or main active ingredient, and is formulated into a pharmaceutically acceptable dosage form with a pharmaceutically acceptable carrier.
[0138] The dosage forms are solid dosage forms suitable for oral administration, liquid dosage forms suitable for oral administration, sterile aqueous or aqueous solutions, dispersions, suspensions or emulsions for parenteral injection, sterile powders for reconstitution into sterile injectable solutions or dispersions, and ointments, powders, patches, sprays or inhalers for topical administration.
[0139] The "safe and effective amount" described in this invention refers to an amount of compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000 mg of the temozolomide derivative of this invention per dose, more preferably, 5-1000 mg of the temozolomide derivative of this invention per dose. Preferably, "one dose" is one capsule or tablet.
[0140] "Pharmaceutically acceptable carriers" refers to one or more compatible solid or liquid fillers or gel substances that are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" means that the components in the composition can be mixed with or with the temozolomide derivatives of this invention without significantly reducing the efficacy of the temozolomide derivatives. Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers, wetting agents (such as sodium dodecyl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0141] There are no particular limitations on the administration of the temozolomide derivatives or pharmaceutical compositions of the present invention. Representative administration methods include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) and local administration.
[0142] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following components: (1) fillers or solubilizers, such as starch, lactose, sucrose, glucose, mannitol, and silica; (2) binders, such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (3) humectants, such as glycerin; (4) disintegrants, such as agar, calcium carbonate, potato starch or cassava starch, alginate, certain complex silicates, and sodium carbonate; (5) slowing agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glyceryl monostearate; (8) adsorbents, such as kaolin; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. Buffers may also be included in capsules, tablets, and pills.
[0143] Solid dosage forms such as tablets, sugar pills, capsules, pellets, and granules can be prepared using coatings and shells, such as casings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compound in such compositions may be delayed at a specific site within the digestive tract. Examples of encapsulating components that may be used are polymeric substances and waxes. If necessary, the active compound may also be formed into microcapsules with one or more of the excipients described above.
[0144] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.
[0145] In addition to these inert diluents, the composition may also contain auxiliaries such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and fragrances.
[0146] In addition to the active compound, the suspension may contain suspending agents such as ethoxylated isooctadecyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitol esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances.
[0147] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.
[0148] Dosage forms of the temozolomide derivatives of this invention for topical administration include ointments, powders, patches, sprays, and inhalers. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or, if necessary, propellants.
[0149] The temozolomide derivative of this invention can be administered alone or in combination with other pharmaceutically acceptable compounds.
[0150] When using the pharmaceutical composition, a safe and effective amount of the temozolomide derivative of the present invention is applied to the mammal (such as a human) requiring treatment. The dosage administered is the pharmaceutically considered effective dose. For a person weighing 60 kg, the daily dose is typically 1–5000 mg, preferably 5–2000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the scope of the skill of a skilled physician.
[0151] Compared with the prior art, the present invention has the following main advantages:
[0152] The temozolomide derivative of this invention enhances the overall anti-glioblastoma effect by inhibiting the PARP1 protein to prevent cells from repairing the damage caused by temozolomide. This is groundbreaking compared to simple structural modifications.
[0153] The temozolomide derivative of this invention can effectively inhibit the proliferation of glioblastoma in vitro, with an inhibition rate superior to that of temozolomide alone at the same dose and the combination of temozolomide and olaparib at the same dose, which is expected to solve the problem of drug resistance to temozolomide. The temozolomide derivative of this invention with PARP inhibitory activity shows promise as a candidate drug for anti-glioblastoma treatment. Detailed Implementation
[0154] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be described in detail below with reference to specific embodiments and comparative examples. Obviously, the described embodiments are merely some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other implementation methods obtained by those skilled in the art without creative effort are within the scope of protection of this invention.
[0155] Unless otherwise specified, the equipment used in this embodiment and experimental examples are all conventional experimental equipment, and the materials and reagents used are all commercially available unless otherwise specified. The experimental methods without special instructions are also conventional experimental methods.
[0156] Example 1: Synthesis of N-(4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)benzyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (Compound 1)
[0157] Step 1: Preparation of 4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)N-Boc-benzylamine (intermediate 1a)
[0158]
[0159] Weigh 1004 mg (4 mmol) of 4-(tert-butoxycarbonyl)amino)methyl)benzoic acid and dissolve it in 4 mL of DMF. Add DIPEA (2090 μL, 12 mmol) and HATU (2280 mg, 6 mmol) and react at room temperature for 15 min to activate the carboxyl group. Then add 725 mg (4.8 mmol) of 2,3-diaminobenzamide and react at room temperature for 4 h. The reaction was confirmed to be complete by TLC. After the reaction was completed, pour the reaction solution into ice water and extract with ethyl acetate. Combine the organic phases and concentrate under vacuum to obtain the crude product. Dissolve the crude product in 4 mL of acetic acid and react at 90 °C for 4 h. Cool to room temperature and concentrate using a vacuum diaphragm pump. Purify by normal phase silica gel column chromatography (EA:PE = 7:3 V / V) to obtain intermediate 1a (yellow-brown solid, 1069 mg, yield 73%).
[0160] Step 2: Synthesis of 4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)-benzylamine (intermediate 1b)
[0161]
[0162] Intermediate 1a (732 mg, 2 mmol) was dissolved in a commercially available 4 M hydrochloric acid ethyl acetate solution and reacted at room temperature for 4 h. TLC monitoring showed the reaction was complete at this point. The reaction mixture was then completely evaporated using a vacuum diaphragm pump to obtain the deamino-protected intermediate 1b hydrochloride (yellowish-brown solid, 600 mg, yield 97%). No further purification was required for the next reaction step.
[0163] Step 3: Synthesis of 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid (intermediate 1c)
[0164]
[0165] 3-Methyl-4-oxo-8-imidazo[5,1-d][1,2,3,5]tetraazine carboxamide (1000 mg, 5.12 mmol) was added to 10 mL of 98% concentrated sulfuric acid under ice bath conditions. NaNO2 (1271 mg, 18.43 mmol) was dissolved in 10 mL of pure water. The NaNO2 solution was added dropwise to the above solution under ice bath conditions. After the addition was completed, the mixture was kept in an ice bath for 45 min and then allowed to return to room temperature. The reaction was allowed to proceed for 12 h. The reaction solution was then added to ice water, and a white solid precipitated out. The solid was filtered and dried to obtain intermediate 1c (white powder, 700 mg, yield 69%).
[0166] Step 4: Synthesis of N-(4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)benzyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (Compound 1)
[0167]
[0168] 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid (intermediate 1c, 164 mg, 0.84 mmol) and HATU (472 mg, 1.24 mmol) were dissolved in 5 mL of DMF. TEA (344 μL, 2.52 mmol) was added dropwise at room temperature with stirring. After the addition was complete, the mixture was reacted at room temperature for 15 min to activate the carboxyl group. Intermediate 1b (274 mg, 0.92 mmol) was then added, and the mixture was reacted at room temperature for 5 h. The reaction was monitored by TLC. The reaction mixture was slowly added dropwise to 10 times the volume of DMF in ice water, followed by extraction with ethyl acetate. The organic phases were combined and evaporated to dryness to obtain the crude product. The crude product was purified by normal-phase silica gel column chromatography (eluent: dichloromethane:methanol = 20:1 V / V) to obtain target compound 1 (white solid, mp 218-220℃, 212 mg, yield 57%). 1 HNMR (300MHz, DMSO-d6) δ: 13.60 (s, 1H), 9.56 (d, J = 3.5Hz, 1H), 9.43 (t, J = 6.3Hz, 1H), 9.10 (s, 1H), 8.40 (d, J = 8.1Hz, 2H), 8.1 1-7.98(m,2H),7.93(dd,J=8.0,1.2Hz,1H),7.76(d,J=8.1Hz,2H),7.54(t,J=7.8Hz,1H),4.79(d,J=6.3Hz,2H),4.07(s,3H). 13C NMR(126MHz,DMSO-d6)δ:177.93,161.69,160.60,157.09,134.85,131.01,120.87,115.88,106.56,101.32 ,94.40,81.70,77.13,76.75,74.35,72.16,70.81,70.64,69.80,61.00,17.85.LC-MS(ESI)m / z:444.1(M+H) + 442.2 (MH) - .
[0169] Example 2: Synthesis of N-(2-(4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)benzamido)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 2)
[0170] Step 1: Preparation of methyl 4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)benzoate (intermediate 2a)
[0171]
[0172] Monomethyl terephthalate (1090 mg, 6 mmol) was dissolved in 6 mL of DMF, and DIPEA (3135 μL, 18 mmol) and HATU (3420 mg, 9 mmol) were added. The reaction was carried out at room temperature for 15 min to activate the carboxyl group. Then, 2,3-diaminobenzamide (907 mg, 6 mmol) was added, and the reaction was carried out at room temperature for 24 h. The reaction was detected by TLC at this point. The reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phases were combined and concentrated under vacuum to obtain the crude product. The crude product was dissolved in 6 mL of acetic acid and reacted at 90 °C for 2.5 h. The reaction solution was cooled to room temperature and concentrated using a vacuum diaphragm pump to obtain the crude product. The crude product was purified by normal phase silica gel column chromatography (EA:PE = 2:1 V / V) to obtain intermediate 2a (yellowish-brown solid, 836 mg, yield 47%).
[0173] Step 2: Synthesis of 4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)-benzoic acid (intermediate 2b)
[0174]
[0175] Intermediate 2a (600 mg, 2.03 mmol) was dissolved in a mixed solvent of 12 mL THF and 3.6 mL methanol (3.3:1 V / V) and stirred at room temperature. LiOH (292 mg, 12.17 mmol) was dissolved in 2.4 mL water to obtain an aqueous solution of LiOH. The aqueous solution of LiOH was added dropwise to the solution of compound 2a. After the addition was complete, the reaction was allowed to proceed at room temperature for 24 h. The hydrolysis reaction was monitored by TCL at this time. The pH was adjusted to neutral by adding 3 M HCl dropwise under ice bath conditions. A large amount of yellowish-brown solid precipitated out. The solid was filtered under reduced pressure and dried to obtain intermediate 2b (yellowish-brown solid, 366 mg, yield 64%).
[0176] Step 3: Synthesis of 2-(4-((2-aminoethyl)carbamoyl)phenyl)-1H-benzo[d]imidazolium-4-carboxamide (intermediate 2c)
[0177]
[0178] Intermediate 2b (281 mg, 1 mmol) and HATU (570 mg, 1.5 mmol) were dissolved in 4 mL of DMF. TEA (417 μL, 3 mmol) was added dropwise while stirring at room temperature. After the addition was complete, the mixture was allowed to react at room temperature for 15 min to activate the carboxyl group. Then, N-Boc-ethylenediamine (176 mg, 1.1 mmol) was added, and the mixture was reacted at room temperature for 5 h. TLC monitoring showed that the reaction was complete at this point. The reaction solution was then slowly added dropwise to 10 times the volume of DMF in ice water, resulting in the precipitation of a milky white solid. After complete precipitation, the solid was filtered under reduced pressure, and the resulting solid was dried to obtain the crude product. The crude product was purified by normal-phase silica gel column chromatography (eluent: EA:PE = 7:3 V / V) to obtain the intermediate (white solid, 220 mg, yield 52%). The intermediate was dissolved in 4 mL of DMF... The amino protecting group was removed by reacting the ethyl acetate solution of 4M hydrochloric acid at room temperature for 3 hours. The reaction solution was then completely evaporated using a vacuum diaphragm pump to give the hydrochloride salt of intermediate 2c (white solid, 115 mg, yield 99%).
[0179] Step 4: Synthesis of N-(2-(4-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)benzamido)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
[0180]
[0181] Following the synthesis in step four of Example 1, intermediate 2c (508 mg, 1.2 mmol) and 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid (195 mg, 1 mmol) were used as reactants. The other reagents, feed ratios, and post-treatment methods were the same, yielding compound 2 (white solid, mp 184-186 °C, yield 53%). 1 H NMR(300MHz, DMSO-d6)δ:13.49(s,1H),8.81(s,1H),8.73(s,1H),8.28(d,J=8.0Hz,2H),8.01(d,J=8 .0Hz,2H),7.85(d,J=7.6Hz,1H),7.79-7.68(m,2H),7.34(t,J=7.7Hz,1H),3.82(s,3H),3.49(s,5H). 13 C NMR(126MHz,DMSO-d6)δ:166.76,166.36,162.81,160.52,151.41,140.15,139.59,136.68,135.97,134.89,131.09,130 .79,128.89,128.41,127.54,123.82,123.50,122.70,116.27,39.02,36.61,36.25,31.23.LC-MS(ESI)m / z:501.2(M+H) + 499.2 (MH) - .
[0182] Example 3: Synthesis of 2-(4-(4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperazine-1-carbonyl)phenyl)-1H-benzo[d]imidazo-4-carboxamide (compound 3)
[0183]
[0184] Following the synthesis of compound 2, N-Boc-ethylenediamine was replaced by 1-(tert-butyloxycarbonyl)piperazine in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 2, yielding compound 3 (white solid, mp 178-180℃, 176 mg, yield 57%). 1H NMR(300MHz,DMSO-d6)δ:13.58(s,1H),9.36(s,1H),8.90(s,1H),8.35(s,2H),7.90(d,J =11.1Hz,2H),7.79(d,J=7.8Hz,1H),7.71(s,2H),7.41(s,1H),3.87(s,4H),3.75(s,4H). 13 C NMR(126MHz,DMSO-d6)δ:170.83,169.13,166.63,161.08,151.58,141.87,139.61,137.75,135.91,134.64,131 .49,130.66,129.23,128.35,127.49,123.57,123.00,115.72,60.23,45.89,38.70,36.57,21.22,14.54,9.12.
[0185] Example 4: Synthesis of N-(2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 4)
[0186] Step 1: Synthesis of tert-butyl (2-(2-fluoro-5-(4-oxo-3,4-dihydrophthalic acid-1-yl)methyl)benzamido)ethyl)carbamate (intermediate 4a)
[0187]
[0188] Weigh 1000 mg (3.35 mmol) of 2-fluoro-5-(4-oxo-3,4-dihydrophthalazine-1-methyl)benzoic acid and HATU (1911 mg, 5.02 mmol) and dissolve them in 8 mL of DMF. Add 1396 μL (10.05 mmol) of TEA dropwise and react at room temperature for 15 min to activate the carboxyl group. Add N-Boc-ethylenediamine (643.2 mg, 4.02 mmol) and react at room temperature for 4 h. Monitor the reaction for completeness by TLC. Slowly add the reaction solution dropwise to 10 times the volume of DMF in ice water. Extract with ethyl acetate and evaporate the organic layer to dryness to obtain the crude product. Purify the crude product by normal-phase silica gel column chromatography (PE:EA = 3:7 V / V) to give an intermediate (white solid, 796 mg, 54% yield). 1H NMR(300MHz,DMSO-d6)δ:12.34(s,1H),8.09(dd,J=8.0,1.8Hz,1H),7.99(s,1H) ,7.99(d,J=10.2Hz,1H),7.94(ddt,J=4.6,2.2,1.0Hz,1H),7.85(dd,J=7.2,1.7 Hz,1H),7.75-7.65(m,2H),7.39-7.33(m,1H),7.24(t,J=8.1Hz,1H),6.46(t,J= 5.1Hz,1H),4.20(t,J=1.0Hz,2H),3.50(q,J=4.5Hz,2H),3.40(q,J=4.7Hz,2H).
[0189] Step 2: Synthesis of N-(2-aminoethyl)-2-fluoro-5-(4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamide hydrochloride (intermediate 4b)
[0190]
[0191] 4a (440 mg, 1 mmol) was dissolved in 9 mL of 4 M hydrochloric acid in ethyl acetate solution. The reaction was carried out at room temperature for 3 h. The reaction was monitored by TLC to confirm that the Boc protecting group was completely removed. The reaction solution was completely evaporated using a vacuum diaphragm pump to give compound 4b (white solid, 372 mg, 99% yield).
[0192] Step 3: Synthesis of N-(2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 4)
[0193]
[0194] 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid (284 mg, 1.46 mmol) and HATU (832 mg, 2.19 mmol) were dissolved in 4 mL of DMF. TEA (609 μL, 4.38 mmol) was added dropwise with stirring at room temperature. After the addition was complete, the mixture was reacted at room temperature for 15 minutes. Then, compound 4b (658 mg, 1.75 mmol) was added, and the reaction was continued at room temperature for 5 hours. TLC monitoring showed that the reaction was complete at this point. The reaction solution was slowly added dropwise to ice water, and the mixture was extracted with ethyl acetate. The organic layers were combined and evaporated to dryness to obtain the crude product. The crude product was purified by normal-phase silica gel column chromatography (DCM:MeOH = 95:5 V / V) to obtain the target compound 4 (white solid, mp 164-166℃, 362 mg, 48% yield). 1 H NMR(300MHz,DMSO-d6)δ:12.63(s,1H),8.88(s,1H),8.67(s,1H),8.46(s,1H),8.28(d,J=7.6Hz,1H),8.04-7 .79(m,3H),7.64(d,J=6.7Hz,1H),7.46(s,1H),7.23(t,J=9.5Hz,1H),4.35(s,2H),3.88(s,3H),3.48(s,4H). 13 CNMR(75MHz,DMSO-d6)δ:164.26,160.46,159.87,156.74,145.43,139.62,134.90,134.75,134.00,133.11,133. 00,132.01,130.69,129.49,128.93,128.27,126.49,125.94,124.25,124.05,39.72,38.82,36.95,36.63,19.01.
[0195] Example 5: Synthesis of N-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)butyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 5)
[0196]
[0197] Following the synthesis process of compound 4, N-Boc-ethylenediamine was replaced with an equimolar amount of N-tert-butoxycarbonyl-1,4-butanediamine. The other raw materials, reagents and preparation methods were the same as those for compound 4, yielding compound 5, a white powder, mp 163-165℃, with a yield of 47%. 1H NMR (300MHz, DMSO-d6) δ: 12.64 (s, 1H), 8.87 (s, 1H), 8.57 (t, J = 5.9Hz, 1H), 8.35 (s,1H),8.27(d,J=7.6Hz,1H),7.99(d,J=7.9Hz,1H),7.86(dt,J=14.7,7.5Hz,2H ),7.57(dd,J=6.8,2.3Hz,1H),7.46(d,J=7.5Hz,1H),7.21(t,J=9.3Hz,1H),4.3 4(s,2H),3.88(s,3H),3.33(d,J=6.1Hz,2H),3.25(d,J=6.1Hz,2H),1.56(s,4H). 13 C NMR(75MHz,DMSO-d6)δ:163.94,160.09,159.85,156.62,145.45,139.68,134.83,133.99,132.80,132.02,131.0 1,130.47,129.50,128.87,128.31,126.51,125.99,124.77,124.57,116.74,116.44,36.91,36.60,27.23,26.97.
[0198] Example 6: Synthesis of N-(6-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)hexyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 6)
[0199]
[0200] Following the synthesis process of compound 4, N-Boc-ethylenediamine was replaced with an equimolar amount of N-Boc-1,6-diaminohexane. The other raw materials, reagents and preparation methods were the same as those for compound 4, yielding compound 5, a white powder, mp 147-149℃, with a yield of 55%. 1H NMR(300MHz,DMSO-d6)δ:12.83(s,1H),9.06(s,1H),8.71(t,J=6.0Hz,1H),8.52-8 .46(m,2H),8.20(d,J=7.8Hz,1H),8.14-8.01(m,2H),7.77(dd,J=6.9,2.3Hz,1H),7 .67(ddd,J=7.8,4.9,2.3Hz,1H),7.42(dd,J=10.3,8.5Hz,1H),4.56(s,2H),4.10(s ,3H),3.52(t,J=6.6Hz,2H),3.43(t,J=6.4Hz,2H),1.81-1.70(m,4H),1.56(s,4H). 13 C NMR(75MHz,DMSO-d6)δ:163.91,160.03,159.86,156.61,145.44,139.67,134.80,133.97,132.73,132.63,132.01,131.08,1 30.46,129.50,128.86,128.31,126.50,125.98,124.87,124.67,116.72,116.42,38.94,36.92,36.59,29.66,29.37,26.59.
[0201] Example 7: Synthesis of N-(8-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoylamino)octyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 7)
[0202]
[0203] Following the same synthesis procedure as compound 4, N-Boc-ethylenediamine was replaced with an equimolar amount of N-Boc-1,8-octanediamine. The other raw materials, reagents, and preparation methods were the same as those for compound 4, yielding compound 7, a white powder with a mp value of 159-161℃ and a yield of 58%. 1HNMR(300MHz,DMSO-d6)δ:12.63(s,1H),8.85(s,1H),8.51(t,J=6.0Hz,1H),8.27(d,J=7.6Hz,2H),8.02-7.78(m,3H),7.58-7.49 (m,1H),7.45(s,1H),7.21(t,J=9.4Hz,1H),4.34(s,2H),3.87(s,3H),3.20(d,J=6.5Hz,2H),1.52(d,J=13.2Hz,3H),1.29(s,8H). 13 C NMR(75MHz,DMSO-d6)δ:163.89,160.00,159.86,156.62,145.42,139.67,134.79,134.72,133.96,132.74,132.63,132.00,131.09, 130.41,129.50,128.85,128.32,126.50,125.97,124.85,124.64,116.73,116.42,39.00,36.93,36.59,29.66,29.36,29.21,26.86.
[0204] Example 8: Synthesis of N-(2-(2-fluoro-N-(2-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamido)ethyl)-5-((4-oxo-3,4-dihydrophthalazine-1-yl)methyl)benzoylamino)ethyl)-3-methyl-4-oxy-3,4-dihydroxyimidazo[5,1-d][1,2,3-5]tetraazine-8-carboxamide (compound 8)
[0205]
[0206] Following the synthesis procedure of compound 4, N-Boc-ethylenediamine was replaced with an equimolar amount of 1,7-bis-Boc-1,4,7-triazaheptane. The rest of the raw materials, reagents and preparation methods were the same as those for compound 4, to obtain compound 8, a white powder, mp 158-160℃, with a yield of 51%. 1H NMR(300MHz, DMSO-d6)δ:12.55(s,1H),8.88(d,J=2.5Hz,2H),8.72-8.62(m,1H),8.57(s,1H),8.23(d,J=7.8Hz,1H),7.97-7.74(m,3H),7.39-7 .23(m,2H),7.12(t,J=8.9Hz,1H),4.19(s,2H),4.04(q,J=7.1Hz,1H),3 .85(d,J=10.8Hz,5H),3.75(s,2H),3.62(d,J=6.2Hz,2H),3.41(s,4H). 13 C NMR(126MHz,DMSO-d6)δ:166.71,160.46,160.18,159.81,157.62,155.68,145.29,139.61,139.58,134.91,134.83,134.77,133.99,131.92, 130.80,130.64,129.48,129.42,128.99,128.95,128.23,126.41,125 .95,125.09,124.94,48.23,46.26,44.35,37.24,36.96,36.63,36.59.
[0207] Example 9: Synthesis of 4-(4-fluoro-3-(4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperazine-1-carbonyl)benzyl)o-phthalazine-1(2H)-one (compound 9)
[0208]
[0209] Following the synthesis procedure of compound 4, N-Boc-ethylenediamine was replaced with 1-(tert-butyloxycarbonyl)piperazine in equal molar amounts. The rest of the raw materials, reagents and preparation methods were the same as those for compound 4, yielding compound 9, a white powder, mp 152-154℃, with a yield of 67%. 1 H NMR(300MHz, DMSO-d6)δ:12.60(d,J=14.8Hz,1H),8.88(s,1H),8.29(d,J=7.6Hz,1H),8.02-7.71(m,3H),7.53-7.37 (m,2H),7.28(t,J=9.7Hz,1H),4.39-4.32(m,2H),3.88(s,3H),3.78(s,2H),3.69(s,3H),3.55(s,1H),3.24(s,1H). 13CNMR(75MHz,DMSO-d6)δ:164.62,162.78,161.06,159.88,155.27,145.34,139.60,135.25,134.72,133.95,132.04,131.37,129.51 ,129.22,128.32,126.53,125.89,124.02,123.78,116.59,116.26,55.38,42.37,36.93,36.60,31.23.LC-MS(ESI)m / z:544.1(M+H) + 542.1 (MH) - .
[0210] Example 10: Synthesis of 3-(2-chloroethyl)-N-(2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 10)
[0211] Step 1: Synthesis of 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (intermediate 10a)
[0212]
[0213] 4-Amino-5-imidazolium carboxamide (3.50 g, 21.5 mmol) was dissolved in 28 mL of 1 M HCl. 42 mL of NaNO2 (1.63 g, 23.7 mmol) aqueous solution was slowly added dropwise in an ice bath at 0 °C. The reaction was allowed to proceed for 30 minutes. The reaction solution was then filtered, the filter cake was washed with water and dried, and then added to EtOAc. The mixture was stirred at room temperature, and 3-chloropropyl isocyanate (8.16 g, 77.3 mmol) was slowly added. The reaction was carried out at room temperature in the dark for 72 h. TLC monitoring showed that the reaction was complete at this point. The reaction solution was diluted with diethyl ether, and a red solid precipitated. The solid was filtered and purified by normal-phase silica gel column chromatography (DCM:MeOH = 97:3 V / V) to obtain intermediate 10a (red solid, 2.50 g, yield 70%). 1 H-NMR (300MHz, DMSO-d6) δ: 8.87 (s, 1H), 7.83 (s, 1H), 7.70 (s, 1H), 4.64 (t, J = 6.1Hz, 2H), 4.03 (t, J = 6.1Hz, 2H) ppm.
[0214] Step 2: Synthesis of 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid (intermediate 10b)
[0215]
[0216] Intermediate 10a (2.50 g, 10.30 mmol) was dissolved in 15 mL of 98% concentrated sulfuric acid and pre-cooled with stirring in an ice bath at 0 °C. 7.5 mL of NaNO2 (2.56 g, 37.1 mmol) aqueous solution was added very slowly dropwise. Gas was released during the addition. After 30 minutes of reaction, the ice bath was removed, and the mixture was allowed to react at room temperature for 3 hours. TLC monitoring showed that the reaction was complete at this point. 100 g of crushed ice was added to the reaction solution, and the mixture was stirred for 3 minutes. A powdery white solid precipitated out. The solid was filtered, the filter cake was washed with ice water, and dried under vacuum to obtain intermediate 10b (powdery white solid, 1.76 g, yield 70%). 1 H-NMR (300MHz, DMSO-d6) δ: 8.86 (s, 1H), 4.65 (t, J = 6.1Hz, 2H), 4.02 (t, J = 6.1Hz, 2H) ppm.
[0217] Step 3: Synthesis of 3-(2-chloroethyl)-N-(2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 10)
[0218]
[0219] Following the synthetic procedure of compound 4, 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid was replaced in equimolar amounts with 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid. The remaining synthetic raw materials, reagents, and preparation methods were the same as those for compound 4. The compound was purified by normal-phase silica gel column chromatography (DCM:MeOH=95:5V / V) to obtain compound 10, a white powder, mp 136-138℃, yield 49%. 1H NMR(300MHz,DMSO-d6)δ:12.59(s,1H),8.91(s,1H),8.66(s,1H),8.41(s,1H),8.26(d,J=7.7Hz,1H),8.03-7.84(m,3H),7.62 (d,J=6.7Hz,1H),7.45(s,1H),7.21(t,J=9.5Hz,1H),4.63(d,J=6.2Hz,2H),4.33(s,2H),4.02(t,J=6.1Hz,2H),3.48(s,4H). 13 C-NMR(126MHz,DMSO-d6)δ:164.24,160.31,159.85,159.37,157.40,145.39,139.53,134.79,134.37,134.00,133. 03,132.01,131.38,130.73,129.65,128.33,126.52,125.97,124.13,116.73,116.55,50.44,41.94,38.87,36.96.
[0220] Example 11: Synthesis of 4-(-3-(4-(3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)o-phthalazine-1(2H)-one (compound 11)
[0221]
[0222] Following the synthesis procedure of compound 10, N-Boc-ethylenediamine was replaced with 1-(tert-butyloxycarbonyl)piperazine in equal molar amounts. The remaining raw materials, reagents, and preparation methods were the same as those for compound 10. The compound 11 was purified by normal-phase silica gel column chromatography (DCM:MeOH = 95:5V / V) to obtain a white powder, mp 130-132℃, with a yield of 62%. 1 H NMR(300MHz, DMSO-d6)δ:12.61(d,J=12.4Hz,1H),8.94(s,1H),8.29(d,J=8.1Hz,1H),8.01-7.80(m,4H),7.44(s,1 H),7.31-7.21(m,1H),4.64(d,J=6.0Hz,2H),4.35(d,J=9.5Hz,2H),4.03(d,J=6.0Hz,2H),3.74(d,J=26.4Hz,8H). 13C NMR(75MHz,DMSO-d6)δ:164.62,160.90,159.88,158.53,155.27,145.35,139.51,135.30,134.32,133.97,132.05,129 .87,129.53,128.34,126.54,125.91,124.02,116.59,116.29,60.25,50.44,46.10,42.34,41.98,36.93,14.54,9.04.
[0223] Example 12: Synthesis of 3-(2-chloroethyl)-N-(6-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)hexyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 12)
[0224]
[0225] Following the synthesis process of compound 10, N-Boc-ethylenediamine was replaced with an equimolar amount of N-Boc-1,6-diaminohexane. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 10, yielding compound 12, a white powder, mp 124-126℃, with a yield of 47%. 1 H NMR(300MHz,DMSO-d6)δ:12.63(s,1H),8.91(s,1H),8.61-8.52(m,1H),8.27(d ,J=8.4Hz,2H),7.99(d,J=7.9Hz,1H),7.87(dt,J=18.6,7.2Hz,2H),7.57-7.53( m,1H),7.45(s,1H),7.21(t,J=9.3Hz,1H),4.65(t,J=6.1Hz,2H),4.34(s,2H),4 .04(td,J=6.6,2.8Hz,3H),2.01(s,1H),1.53(s,4H),1.34(s,5H),1.19(s,1H). 13C NMR(126MHz,DMSO-d6)δ:163.91,159.85,159.23,157.27,145.42,139.57,134.78,134.25,133.97,132.01,131.76,130.44,12 9.58,128.35,126.52,125.99,124.85,124.73,116.66,116.48,60.23,50.40,41.95,38.99,36.93,29.62,29.36,21.22,14.55.
[0226] Example 13: Synthesis of 2-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-yl)-1H-benzo[d]imidazo-4-carboxamide (compound 13)
[0227]
[0228] Following the synthesis procedure in step one of Example 1, 2,3-diaminobenzamide (192 mg, 1.27 mmol) and 3-methyl-4-oxo-3,4-dihydroimidazole[5,1-d][1,2,3,5]tetraazine-8-carboxylic acid (225 mg, 1.153 mmol) were dissolved in 6 mL of DMF. HATU (655.5 mg, 1.725 mmol) and DIPEA (400 μL, 2.3 mmol) were added, and the reaction was carried out at room temperature for 5 h. The reaction solution was then added dropwise to 10 times the volume of DMF in ice water, extracted with ethyl acetate, and the organic phases were combined and evaporated to dryness. Acetic acid was added, and the mixture was refluxed at 90 °C. The reaction was monitored by TLC until complete, and then evaporated to dryness. The mixture was purified by normal-phase silica gel column chromatography (DCM:MeOH = 96:4 V / V) to obtain compound 13, a yellow powder, 124 mg, with a yield of 30%. It exhibits fluorescence absorption at 365 nm. 1 H NMR (300MHz, DMSO-d6) δ: 13.43 (s, 1H), 9.32 (s, 1H), 8.88 (s, 1H), 7.78–7.67 (m, 2H), 7.60 (d, J = 7.9Hz, 1H), 7.23 (s, 1H), 3.74 (s, 3H), 1.07 (s, 1H). 13 C NMR (100MHz, DMSO-d6) δ: 168.67, 151.18, 144.03, 141.56, 139.30, 137.70, 134.76, 126.91, 123.92, 123.53, 121.74, 116.54, 34.73.
[0229] Example 14: Synthesis of 2-(4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)-1H-benzo[d]imidazo-7-carboxamide (compound 14)
[0230]
[0231] Following the same synthetic procedure as Compound 1, 4-BOC-2-morpholinocarboxylic acid was used to replace 4-((tert-butoxycarbonyl)amino)methyl)benzoic acid in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for Compound 1, yielding Compound 14, a pale yellow powder, with an overall yield of 20%. 1 H NMR(300MHz, DMSO-d6)δ:12.27(s,1H),8.79(s,1H),7.85(ddd,J=17.3,7.6,1.1Hz,2H),7.51(d,J=6.0Hz,3H),4.98 (t,J=2.3Hz,1H),4.35(dd,J=12.4,2.2Hz,1H),4.17(dd,J=12.4,2.3Hz,1H),4.14-4.01(m,2H),3.89-3.68(m,5H). 13 C NMR(75MHz,DMSO-d6)δ:168.51,160.51,154.92,143.09,140.87,137.39,136.48,1 32.50,131.72,126.34,121.98,121.01,120.22,72.51,65.19,48.08,44.67,34.71.
[0232] Example 15: Synthesis of N-(2-(2-((4-carbamoyl-1H-benzo[d]imidazol-2-yl)methoxy)ethoxy)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 15)
[0233]
[0234] Following the synthesis procedure of compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced by 1-tert-butyl 5,8,11-trioxa-2-azatridecanoic acid in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 14, yielding compound 15, a pale yellow powder, with an overall yield of 10%. 1H NMR(300MHz, DMSO-d6)δ:12.14(s,1H),9.19(t,J=5.6Hz,1H),8.78(s,1H),8.19(s,2H),7.88(dd,J=8.5,1.4Hz,1H),7.51(dd,J=9.0,1.3Hz ,1H),7.41(dd,J=9.0,8.4Hz,1H),4.64(s,2H),3.84(s,2H),3.72-3.64(m,4H),3.64-3.53(m,4H),3.43(dt,J=5.6,4.1Hz,2H),2.94(s,3H). 13 C NMR (75MHz, DMSO-d6) δ: 167.48, 160.87, 154.75, 142.66, 140.95, 138.63, 137.33, 132.14, 131 .27,126.37,122.91,121.30,116.65,70.55,70.01,69.68,69.61,69.44,66.68,40.07,34.71.
[0235] Example 16: Synthesis of N-(2-(2-((4-carbamoyl-1H-benzo[d]imidazol-2-yl)methoxy)ethoxy)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 16)
[0236]
[0237] Following the synthesis procedure of compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced by 2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxyacetic acid in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 14, yielding compound 16, a pale yellow powder, with an overall yield of 15%. 1 H NMR(300MHz, DMSO-d6)δ:11.94(s,1H),9.24(t,J=5.6Hz,1H),8.78(s,1H),8.19(s,2H),7.88(dd,J=8.5,1.4Hz,1H),7.51(dd,J=9.0,1.3H z,1H),7.41(dd,J=9.1,8.4Hz,1H),4.64(s,2H),3.68(td,J=4.6,0.8Hz,2H),3.64-3.54(m,4H),3.43(dt,J=5.6,4.1Hz,2H),3.14(s,3H). 13C NMR(75MHz,DMSO-d6)δ:167.48,160.87,154.75,142.66,140.95,138.63,137.33,132. 14,131.27,126.37,122.91,121.30,116.65,69.67,69.60,69.44,66.68,40.07,34.71.
[0238] Example 17: Synthesis of N-(2-((4-carbamoyl-1H-benzimidazol-2-yl)methoxy)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 17)
[0239]
[0240] Following the synthetic procedure of compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced with 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetic acid. The remaining synthetic raw materials, reagents, preparation methods, and purification methods were the same as those for compound 14, yielding compound 17, a pale yellow powder, with an overall yield of 15%. 1 H NMR(300MHz,DMSO-d6)δ:11.94(s,1H),9.37(t,J=5.6Hz,1H),8.78(s,1H),8.19(s,2H),7.88(dd,J=8.5,1.4Hz,1H),7.51(dd ,J=9.0,1.3Hz,1H),7.41(dd,J=9.1,8.4Hz,1H),4.56(s,2H),3.80(t,J=4.0Hz,2H),3.50(dt,J=5.6,4.0Hz,2H),3.32(s,3H). 13 C NMR(75MHz,DMSO-d6)δ:167.48,160.87,154.60,142.66,140.95,138.63,137.3 3,132.14,131.26,126.37,122.91,121.30,116.65,69.05,66.56,40.10,34.71.
[0241] Example 18: Synthesis of 2-(1-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carbonyl)-2,5-dihydro-1H-pyrrole-2-yl)-1H-benzo[d]imidazolium-4-carboxamide (compound 18)
[0242]
[0243] Following the synthetic procedure of compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced by an equimolar amount of 1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrole-2-carboxylic acid. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 14, yielding compound 18, a pale yellow powder, with an overall yield of 15%. 1 H NMR(300MHz,DMSO-d6)δ:12.14(s,1H),8.79(s,1H),7.97-7.84(m,3H),7.61 (dd,J=9.1,1.1Hz,1H),7.41(t,J=8.8Hz,1H),6.48(ddt,J=7.7,5.1,1.0Hz, 1H),6.19(dtd,J=7.6,2.1,1.0Hz,1H),5.58(dq,J=5.1,1.0Hz,1H),4.99(dd t,J=12.4,2.0,1.0Hz,1H),3.98(ddt,J=12.4,2.1,1.0Hz,1H),2.92(s,3H). 13 C NMR(75MHz,DMSO-d6)δ:167.49,161.69,153.73,143.35,140.87,138.37,137.97,13 2.33,131.72,130.71,128.04,126.58,123.18,121.19,119.30,65.56,49.69,34.71.
[0244] Example 19: Synthesis of N-(1-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)-2-(methylthio)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 19)
[0245]
[0246] Following the synthetic procedure of compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced by 2-((tert-butoxycarbonyl)amino)-3-(methylthio)propionic acid in equal molar amounts. The other raw materials, reagents and preparation methods were the same as those for compound 14, yielding compound 19, a pale yellow powder with an overall yield of 20%. 1H NMR (300MHz, DMSO-d6) δ: 12.50 (s, 1H), 9.08 (d, J = 7.7Hz, 1H), 8.98 (s, 1H), 7.97-7.84 (m, 3H), 7.61 ( dd,J=9.1,1.1Hz,1H),7.47-7.35(m,1H),5.46-5.35(m,1H),3.84(s,3H),3.24(s,1H),2.76(s,3H). 13 C NMR(75MHz,DMSO-d6)δ:167.48,161.06,155.95,142.82,140.95,138.01,137.8 0,132.16,131.55,126.49,123.19,121.22,119.30,54.33,35.47,34.71,16.12.
[0247] Example 20: Synthesis of N-(1-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)-2-(methylthio)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 20)
[0248]
[0249] Following the synthesis process of compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced by an equimolar amount of Boc-D-ortholeucine. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 14, yielding compound 20, a pale yellow powder, with an overall yield of 20%. 1 H NMR(300MHz,DMSO-d6)δ:12.11(s,1H),9.27(d,J=8.2Hz,1H),8.85(s,1H),7.97-7.84(m,3H),7.61(dd,J=9.1,1.1Hz,1H) ,7.41(t,J=8.8Hz,1H),5.11(dt,J=8.2,4.8Hz,1H),3.08(s,3H),2.11-1.97(m,2H),1.51-1.25(m,4H),0.94-0.83(m,3H). 13 C NMR(75MHz,DMSO-d6)δ:167.48,161.60,159.06,146.38,140.20,137.79,137.17,131. 89,128.92,126.50,123.19,121.08,119.32,49.92,34.71,31.82,28.40,22.25,13.93.
[0250] Example 21: Synthesis of N-(1-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)-2-methylpropyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 21)
[0251]
[0252] Following the same synthetic procedure as compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced with Boc-L-valine in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as for compound 14, yielding compound 21, a pale yellow powder, with an overall yield of 15%. 1 H NMR(300MHz, DMSO-d6)δ:12.35(d,J=8.7Hz,1H),9.38(s,1H),8.70(s,1H),7.97-7.84(m,3H),7.61(dd,J=9.1,1.1Hz,1H),7.41(t,J=8 .8Hz,1H),5.01(dddd,J=8.3,5.3,3.0,1.5Hz,1H),3.16(s,3H),2.35(dtd,J=13.9,6.9,5.3Hz,1H),1.01(dddd,J=7.0,1.5,0.7Hz,6H). 13 C NMR(75MHz,DMSO-d6)δ:167.48,161.96,157.20,146.38,140.20,137.45,136.7 6,131.89,129.18,126.50,123.19,121.08,119.30,55.55,34.71,30.48,18.69.
[0253] Example 22: Synthesis of 2-((4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)methyl)-1H-benzo[d]imidazo-4-carboxamide (compound 22)
[0254]
[0255] Following the synthesis process of compound 14, 4-BOC-2-morpholinoacetic acid was replaced with 4-BOC-2-morpholinocarboxylic acid in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 14, yielding compound 22, a pale yellow powder, with an overall yield of 20%. 1H NMR(300MHz, DMSO-d6)δ:12.15(s,1H),8.19(s,1H),7.99(s,2H),7.88(dd,J=8.6,1.3Hz,1H),7.51(dd,J=8.9,1.4Hz,
[0256] 1H),7.47-7.35(m,1H),4.10(tt,J=6.3,4.0Hz,1H),3.99(dd,J=12.4,4.1Hz,1H),3.84(s,3H),3.91-3.56(m,5H),2.98(dd,J=6.3,0.6Hz,2H). 13 C NMR(75MHz,DMSO-d6)δ:167.48,160.71,152.25,142.91,140.87,138.20,136.84,132. 41,131.72,126.28,122.91,121.51,116.65,73.95,64.98,50.35,44.76,35.59,34.71.
[0257] Example 23: Synthesis of N-(2-(2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)ethoxy)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 23)
[0258]
[0259] Following the synthesis procedure of compound 4, N-Boc-ethylenediamine was replaced by an equimolar amount of [2-(2-aminoethoxy)ethyl]carbamate tert-butyl ester. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 23, a white powder with an overall yield of 15%. 1 H NMR(300MHz,DMSO-d6)δ:12.59(s,1H),8.81(s,1H),8.78(s,1H),8.14-8.02(m ,1H),7.99-7.88(m,2H),7.85(dd,J=7.0,2.2Hz,1H),7.78-7.62(m,2H),7.36(d ddt,J=8.0,5.1,2.0,1.0Hz,1H),7.24(t,J=8.1Hz,1H),4.20(t,J=1.0Hz,2H),3 .86(s,3H),3.84(s,2H),3.59(d,J=0.7Hz,1H),3.57(s,1H),3.55-3.38(m,4H). 13C NMR(75MHz,DMSO-d6)δ:165.19,165.08,160.87,160.28,159.75,156.92,151.25,142.66,140.95,132.17,132.14,132.10,132.06,132.03,1 31.27,131.24,130.73,130.62,128.74,128.35,126.35,125.41,121. 44,121.17,116.11,115.85,69.34,69.33,40.16,40.07,36.73,34.71.
[0260] Example 24: Synthesis of N-(2-(2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzamido)ethoxy)ethoxy)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 24)
[0261]
[0262] Following the same synthesis procedure as compound 4, N-Boc-ethylenediamine was replaced by 2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate tert-butyl ester. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 24, a white powder with an overall yield of 10%. 1 H NMR (300MHz, DMSO-d6) δ: 12.15 (s, 1H), 9.27 (t, J = 5.6Hz, 1H), 8.78 (s, 1H), 8.1 4-8.02(m,1H),7.99-7.88(m,2H),7.85(dd,J=7.0,2.2Hz,1H),7.78-7.62(m,2 H),7.36(dddt,J=7.9,5.1,2.0,1.0Hz,1H),7.24(t,J=8.1Hz,1H),4.20(t,J=1 .0Hz,2H),3.92(s,3H),3.84(s,2H),3.60(d,J=8.1Hz,2H),3.56-3.38(m,4H). 13CNMR(75MHz,DMSO-d6)δ:165.10,165.00,160.87,160.28,159.75,156.92 ,151.25,142.66,140.95,132.17,132.14,132.10,132.06,132.03,131.27 ,131.24,130.73,130.63,128.74,128.35,126.35,125.41,121.44,121.17 ,116.11,115.85,69.65,69.64,69.47,69.46,40.19,40.08,36.73,34.71.
[0263] Example 25: Synthesis of N-(1-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)phenyl)-1-oxo-5,8,11-trioxa-2-azatridecane-13-yl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 25)
[0264]
[0265] Following the same synthetic procedure as compound 4, N-Boc-ethylenediamine was replaced by N-Boc-1,11-diamino-3,6,9-trioxaundecan in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 25, a white powder with an overall yield of 10%. 1 H NMR (400MHz, DMSO-d6) δ: 12.34 (s, 1H), 9.07 (s, 1H), 9.07 (d, J = 11.2Hz, 1H), 8.78 (s, 1 H),8.13-8.06(m,1H),7.98-7.89(m,2H),7.88-7.81(m,1H),7.77-7.64(m,2H),7.36( dddt,J=7.9,5.0,2.0,0.9Hz,1H),7.24(t,J=8.1Hz,1H),4.20(t,J=1.0Hz,2H),3.84( s,3H),3.59(d,J=4.1Hz,3H),3.51(dt,J=5.4,4.3Hz,2H),3.43(dt,J=5.7,4.2Hz,2H). 13C NMR(75MHz,DMSO-d6)δ:165.10,165.00,160.87,160.28,159.75,156.92, 151.25,142.66,140.95,132.17,132.14,132.10,132.06,132.03,131.27, 131.24,130.73,130.62,128.74,128.35,126.35,125.41,121.44,121.17 ,116.11,115.85,70.55,69.68,69.47,69.46,40.19,40.08,36.73,34.71.
[0266] Example 26: Synthesis of 2-(2-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carbamate)ethoxy)ethyl 2-fluoro-5-((4-oxo-3,7-dihydrophthalazine-1-yl)methyl)benzoate (compound 26)
[0267]
[0268] Following the same synthesis procedure as compound 4, N-Boc-ethylenediamine was replaced by equimolar amounts of 2-(2-BOC-aminoethoxy)ethanol. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 26, a white powder with an overall yield of 15%. 1 H NMR (400MHz, DMSO-d6) δ: 12.58 (s, 1H), 8.79-8.75 (m, 1H), 8.38 (t, J = 5.9Hz, 1H), 8.26 ( dd,J=7.8,1.5Hz,1H),7.96(dd,J=8.1,1.3Hz,1H),7.89(td,J=8.1,7.6,1.5Hz,1H),7.8 6-7.79(m,2H),7.59(ddd,J=8.5,4.6,2.5Hz,1H),7.25(dd,J=10.8,8.5Hz,1H),4.43-4. 33(m,4H),3.86(s,3H),3.80-3.72(m,2H),3.62(t,J=5.9Hz,2H),3.49(q,J=5.9Hz,2H). 13C NMR(75MHz,DMSO-d6)δ:164.70,164.60,160.87,160.83,159.75,157.47,151.23,142.66,140.95,132.55,132.44,132.17,132.14,131.27,1 31.24,131.23,130.96,130.85,128.74,128.35,126.35,125.41,118. 47,118.20,116.44,116.17,69.38,68.76,64.29,40.06,36.71,34.71.
[0269] Example 27: Synthesis of ethyl 2-(2-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carboxamido)ethoxy)ethoxy)ethyl-2-fluoro-5-(4-oxo-3,7-dihydrophthalazine-1-yl)methyl)benzoate (compound 27)
[0270]
[0271] Following the synthesis procedure of compound 4, N-Boc-ethylenediamine was replaced by an equimolar amount of tert-butyl 2-(2-(2-(hydroxyethoxy)ethoxy)ethylcarbamate. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 27, a white powder with an overall yield of 10%. 1 HNMR(400MHz,DMSO-d6)δ:12.59(d,J=6.2Hz,1H),8.31-8.23(m,1H),7.98(d dt,J=7.1,5.8,1.4Hz,1H),7.91(ddd,J=8.1,7.2,1.6Hz,1H),7.87-7.79(m,2 H),7.77-7.69(m,1H),7.65(dq,J=6.0,2.3Hz,1H),7.34-7.25(m,1H),5.76( s,4H),4.43-4.33(m,3H),3.76-3.68(m,2H),3.63-3.54(m,4H),3.35(s,5H). 13CNMR(75MHz,DMSO-d6)δ:164.70,164.60,160.87,160.83,159.75,157.47 ,151.23,142.66,140.95,132.55,132.44,132.17,132.14,131.27,131.24 ,131.23,130.96,130.85,128.74,128.35,126.35,125.41,118.47,118.20 ,116.44,116.17,70.56,69.68,69.44,68.86,64.29,40.07,36.71,34.71.
[0272] Example 28: Synthesis of 1-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-yl)-1-oxo-5,8,11-trioxa-2-azatridecane-13-yl-2-fluoro-5-(4-oxo-3,7-dihydrophthalazine-1-yl)methyl)benzoate (compound 28)
[0273]
[0274] Following the synthesis procedure of compound 4, N-Boc-ethylenediamine was replaced by tert-butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate in equal molar amounts as an intermediate. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 28, a white powder with an overall yield of 6%. 1 H NMR (300MHz, DMSO-d6) δ: 12.34 (s, 1H), 9.07 (s, 1H), 9.24 (d, J = 11.2Hz, 1H), 8.73 (s, 1H), 8.1 3-8.06(m,1H),7.97(ddt,J=5.1,2.1,1.1Hz,1H),7.88-7.81(m,1H),7.77-7.64(m,2H),7.37-
[0275] 7.24(m,2H),4.43(t,J=5.1Hz,2H),4.21(t,J=1.1Hz,2H),3.84(s,3H),3.69(t,J=5.1Hz,2H),3.62-3.53(m,6H),3.43(dt,J=5.7,4.2Hz,2H). 13C NMR(75MHz,DMSO-d6)δ:164.70,164.60,160.86,160.83,159.75,157.47,151 .23,142.66,140.95,132.55,132.44,132.17,132.14,131.27,131.24,131.23 ,130.96,130.85,128.74,128.35,126.35,125.41,118.47,118.20,116.44,116.17,70.68,70.55,70.52,69.68,69.44,68.86,64.29,40.07,36.71,34.71.
[0276] Example 29: Synthesis of 2-fluoro-N-((1R,5S,6S)-3-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)-5-((4-oxo-3,7-dihydrophthalazine-1-yl)methyl)benzamide (compound 29)
[0277]
[0278] Following the synthesis procedure of compound 4, N-Boc-ethylenediamine was replaced by tert-butyl rel-(1R,5S,6S)-6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylic acid with an equimolar substitution. The other raw materials, reagents and preparation methods were the same as those for compound 4, yielding compound 29, a white powder with an overall yield of 15%. 1 HNMR(300MHz,DMSO-d6)δ:12.34(s,1H),8.79(s,1H),8.13-8.06(m,1H),8.00(ddt,J=4.9 ,1.9,1.0Hz,1H),7.88-7.82(m,1H),7.79(d,J=7.0Hz,1H),7.76-7.64(m,2H),7.36(dddt ,J=7.9,5.1,2.0,0.9Hz,1H),7.24(t,J=8.1Hz,1H),4.20(t,J=1.0Hz,2H),3.83-3.75(m, 2H),3.64(dd,J=12.3,2.3Hz,2H),3.54(q,J=6.5Hz,1H),3.13(s,3H),1.90-1.79(m,2H). 13C NMR(75MHz,DMSO-d6)δ:166.00,165.90,162.19,160.55,160.53,157.19,151.92,146.17,139.95,132.17,132.12,132.08,132.07,131.4 6,131.01,130.55,130.34,130.23,129.12,128.74,126.35,125.41, 122.12,121.86,116.10,115.83,49.29,34.88,34.71,31.37,22.88.
[0279] Example 30: Synthesis of (4-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)methyl-2-fluoro-5-((4-oxo-3,4-dihydrophthalazine-1-yl)methyl)benzoate (compound 30)
[0280]
[0281] Following the same synthesis procedure as compound 4, N-Boc-ethylenediamine was replaced by 4-Boc-2-hydroxymethylmorpholine in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 30, a white powder with an overall yield of 20%. 1 HNMR(300MHz,DMSO-d6)δ:12.58(s,2H),8.84(d,J=6.6Hz,2H),8.26(dd,J=7.7,1.6Hz,2H),8.03-7.75(m ,7H),7.63(d,J=8.8Hz,2H),7.28(dt,J=15.9,9.6Hz,2H),4.38(d,J=6.6Hz,5H),3.83(d,J=13.3Hz,7H). 13 C NMR(75MHz,DMSO-d6)δ:164.76,164.66,160.84,160.74,159.75,157.48, 151.23,142.92,140.87,132.55,132.44,132.36,132.17,131.72,131.27, 131.24,131.23,130.96,130.85,128.74,128.35,126.35,125.41,117.88, 117.62,116.44,116.17,74.12,65.27,65.05,49.02,44.69,36.71,34.71.
[0282] Example 31: Synthesis of 2-fluoro-N-((4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)methyl)-5-(4-oxo-3,7-dihydrophthalazine-1-yl)methyl)benzamide (compound 31)
[0283]
[0284] Following the synthesis procedure of compound 4, N-Boc-ethylenediamine was replaced by 2-aminomethyl-4-Boc-morpholine in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 31, a white powder with an overall yield of 25%. 1 H NMR(300MHz, DMSO-d6)δ:12.58(s,1H),8.79(s,1H),8.13-8.01(m,2H),7.94(ddt,J=5.1,2.0,1.1Hz,1H),7.88-7.81(m,1H),7.77-7.64(m,2H),7 .36(dddt,J=7.9,5.0,2.0,0.9Hz,1H),7.24(t,J=8.1Hz,1H),4.25(q,J= 3.5Hz,1H),4.20(t,J=1.0Hz,2H),3.85-3.59(m,7H),3.59-3.44(m,2H). 13 C NMR(75MHz,DMSO-d6)δ:165.31,165.21,160.72,160.28,159.75,156.92, 151.25,142.91,140.87,132.40,132.17,132.14,132.10,132.06,132.03, 131.72,131.24,130.73,130.62,128.74,128.35,126.35,125.41,121.81, 121.54,116.11,115.85,73.94,64.73,48.83,44.76,44.16,36.73,34.71.
[0285] Example 32: Synthesis of 2-fluoro-N-methyl-N-((1-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperidin-3-yl)methyl)-5-(4-oxo-3,4-dihydrophthalazine-1-yl)methyl)benzamide (compound 32)
[0286]
[0287] Following the synthesis process of Example 4, 1-Boc-3-[(methylamino)methyl]piperidine was used to replace N-Boc-ethylenediamine in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 32, a white powder with an overall yield of 16%. 1 H NMR(300MHz,DMSO-d6)δ:12.34(s,1H),8.95(s,1H),8.13-8.06(m,1H),7.88-7.82(m,1H),7.80(ddt, J=5.0,2.1,1.1Hz,1H),7.77-7.64(m,2H),7.33(dddt,J=8.0,5.1,2.0,1.0Hz,1H),7.25(t,J=8.1Hz,1 H),4.20(t,J=1.0Hz,2H),3.84(s,3H),3.75(dd,J=12.5,4.8Hz,1H),3.58(ddd,J=12.3,6.1,3.7Hz,1H ),3.52-3.37(m,3H),3.20(dd,J=11.4,5.7Hz,1H),2.96(s,3H),2.33-2.20(m,1H),1.83-1.51(m,4H). 13 C NMR(75MHz,DMSO-d6)δ:167.71,167.60,160.92,159.79,159.75,156.43,151 .25,142.52,140.87,132.17,132.08,132.00,131.98,131.91,131.87,131.72 ,131.24,129.61,129.50,128.74,128.35,126.35,125.41,123.67,123.40,115.60,115.33,51.58,48.74,46.58,36.37,36.09,34.71,34.01,27.12,24.12.
[0288] Example 33: Synthesis of 4-(4-fluoro-3-(2-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carbonyl)-2,8-diazaspiro[4,5]decane-8-carbonyl]benzyl)phthalazine-1(2H)-one (compound 33)
[0289]
[0290] Following the synthesis process of compound 4, 2,8-diazaspiro[4.5]dec-2-carboxylic acid tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, resulting in compound 33, a white powder with an overall yield of 15%. 1 H NMR(300MHz, DMSO-d6)δ:12.25(s,1H),9.13(s,1H),8.13-8.06(m,1H),7.88-7.81(m,1H),7.77-7.64(m,3H),7.33(dddt,J=7.9,5.0,1.8 ,0.9Hz,1H),7.25(t,J=8.1Hz,1H),4.20(t,J=1.0Hz,2H),3.89(s,3H),3.68-3.39(m,9H),1.92-1.72(m,4H),1.68(dd,J=4.6,2.8Hz,1H). 13 C NMR(75MHz,DMSO-d6)δ:166.25,166.15,161.94,159.81,159.75,156.45,15 1.25,142.52,140.87,132.17,132.12,132.06,132.02,131.97,131.93,131 .72,131.24,129.87,129.76,128.74,128.35,126.35,125.41,123.19,122.92,115.57,115.31,56.34,46.55,42.65,42.52,37.15,36.43,34.71,34.28.
[0291] Example 34: Synthesis of 2-fluoro-N-((1-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperidin-3-yl)methyl)-5-(4-oxo-3,4-dihydrophthalazine-1-yl)methyl)benzamide (compound 34)
[0292]
[0293] Following the same synthesis procedure as compound 4, 1-Boc-3-aminomethylpiperidine was used to replace N-Boc-ethylenediamine in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 34, a white powder with an overall yield of 20%. 1HNMR(300MHz,DMSO-d6)δ:12.17(s,1H),8.71(s,1H),8.13-8.06(m,1H),8.02-7.91(m,2H),7. 88-7.81(m,1H),7.77-7.64(m,2H),7.36(dddt,J=7.9,5.0,2.0,0.9Hz,1H),7.24(t,J=8.1Hz,1 H),4.20(t,J=1.0Hz,2H),3.93(s,3H),3.72(dd,J=12.4,4.5Hz,1H),3.58(ddd,J=12.3,6.0,3. 8Hz,1H),3.48-3.37(m,2H),3.32-3.16(m,2H),2.23(tp,J=6.4,4.8Hz,1H),1.81-1.49(m,4H). 13 C NMR(75MHz,DMSO-d6)δ:165.20,165.09,160.92,160.28,159.75,156.92,15 1.25,142.52,140.87,132.17,132.14,132.09,132.05,132.03,132.00,131 .72,131.24,130.61,130.51,128.74,128.35,126.35,125.41,121.76,121.49,116.11,115.85,48.41,46.58,44.49,36.73,34.71,34.51,26.78,24.08.
[0294] Example 35: Synthesis of 3-methyl-4-oxo-N-(2-(2-(2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamyl)ethoxy)ethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 35)
[0295]
[0296] Following the synthetic procedure of compound 4, N-Boc-ethylenediamine was replaced by equimolar amounts of [2-(2-aminoethoxy)ethyl]carbamate tert-butyl ester, and 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid was replaced by equimolar amounts of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid. The remaining synthetic raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 35, a white powder, with an overall yield of 15%. 1H NMR (300MHz, DMSO-d6) δ: 12.42 (s, 1H), 9.07 (s, 1H), 9.07 (d, J = 11.2Hz, 1H), 8.78 (s, 1H),8.06(dd,J=7.9,1.8Hz,1H),7.96-7.89(m,1H),7.84-7.76(m,2H),7.72(td,J=7 .9,1.6Hz,1H),3.89(d,J=17.1Hz,1H),3.84(s,3H),3.82(d,J=17.4Hz,1H),3.58(t, J=4.2Hz,2H),3.52(t,J=4.3Hz,2H),3.47-3.39(m,2H),3.31(dt,J=5.0,4.2Hz,2H). 13 C NMR(75MHz,DMSO-d6)δ:170.75,160.87,159.69,147.68,142.66,140.95,132.15,132.14,1 31.27,130.51,128.74,128.35,126.38,125.31,69.33,69.30,40.10,40.07,37.80,34.71.
[0297] Example 36: Synthesis of 3-methyl-4-oxo-N-(2-(2-(2-(2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamido)ethoxy)ethoxy)ethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 36)
[0298]
[0299] Following the synthetic procedure of compound 4, 2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 36, a white powder, with an overall yield of 13%. 1H NMR (300MHz, DMSO-d6) δ: 12.42 (s, 1H), 9.23 (s, 1H), 9.07 (d, J = 11.2Hz, 1H), 8.78 (s, 1H) ),8.06(dd,J=7.9,1.7Hz,1H),7.96-7.89(m,1H),7.84-7.76(m,2H),7.72(td,J=7.9,1 .7Hz,1H),4.05(d,J=17.1Hz,1H),3.92(s,3H),3.82(d,J=17.4Hz,1H),3.60(d,J=8.4H z,1H),3.55(t,J=4.4Hz,4H),3.43(dt,J=5.7,4.2Hz,4H),3.30(dt,J=5.1,4.4Hz,2H). 13 C NMR(75MHz,DMSO-d6)δ:170.68,160.87,159.69,147.68,142.66,140.95,132.15,132.14,131.27, 130.51,128.74,128.35,126.38,125.31,69.65,69.64,69.50,69.47,40.09,40.07,37.80,34.71.
[0300] Example 37: Synthesis of 3-methyl-4-oxo-N-(2-oxo-1-(4-oxo-3,4-dihydrophthalazin-1-yl)-6,9,12-trioxa-3-azatetradecane-14yl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 37)
[0301]
[0302] Following the synthetic procedure of compound 4, N-Boc-ethylenediamine was replaced by N-Boc-1,11-diamino-3,6,9-trioxaundecan in equal molar amounts, and 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid was replaced by 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 37, a white powder, with an overall yield of 10%. 1H NMR (300MHz, DMSO-d6) δ: 12.42 (s, 1H), 9.07 (s, 1H), 9.07 (d, J = 11.2Hz, 1H), 8.7 8(s,1H),8.06(dd,J=7.8,1.8Hz,1H),7.96-7.89(m,1H),7.84-7.76(m,2H),7.72 (td,J=7.9,1.6Hz,1H),3.89(d,J=17.1Hz,1H),3.84(s,3H),3.82(d,J=17.4Hz, 1H),3.62-3.52(m,8H),3.43(dt,J=5.7,4.2Hz,2H),3.31(dt,J=5.3,4.4Hz,2H). 13 C NMR(75MHz,DMSO-d6)δ:170.68,160.87,159.69,147.68,142.66,140.95,132.15,132.14,131.27, 130.51,128.74,128.35,126.38,125.31,70.55,69.68,69.50,69.47,40.09,40.07,37.80,34.71.
[0303] Example 38: Synthesis of 2-(2-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carboxamido)ethoxy)ethyl-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetate (compound 38)
[0304]
[0305] Following the synthetic procedure of compound 4, 2-(2-BOC-aminoethoxy)ethanol was used to replace N-Boc-ethylenediamine in equimolar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 38, a white powder, with an overall yield of 15%. 1H NMR(300MHz, DMSO-d6)δ:12.52(s,1H),9.07(s,1H),9.07(d,J=11.2Hz,1H),8.78(s,1H),8.09-8.02(m,1H),7.94(dd,J=7.2,1.9Hz,1H),7.79(td ,J=7.6,1.7Hz,1H),7.72(td,J=7.9,1.7Hz,1H),4.22(t,J=5.3Hz,2H),4 .02(s,2H),3.89(s,3H),3.67-3.56(m,4H),3.43(dt,J=5.7,4.2Hz,2H). 13 C NMR(75MHz,DMSO-d6)δ:168.98,160.87,159.74,144.55,142.66,140.95,132.19,132.14,1 31.27,130.24,128.74,127.76,126.88,126.38,69.38,68.80,63.72,40.06,37.03,34.71.
[0306] Example 39: Synthesis of 2-(2-(2-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carboxamido)ethoxy)ethoxy)ethyl)-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetate (compound 39)
[0307]
[0308] Following the synthetic procedure of compound 4, 2-(2-(2-(hydroxyethoxy)ethoxy)ethylcarbamate tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 39, a white powder, with an overall yield of 10%. 1H NMR(300MHz,DMSO-d6)δ:12.52(s,1H),9.07(s,1H),9.07(d,J=11.2Hz,1H),8 .78(s,1H),8.09-8.02(m,1H),7.94(dd,J=7.2,1.9Hz,1H),7.79(td,J=7.6,1. 6Hz,1H),7.72(td,J=7.9,1.7Hz,1H),4.22(t,J=5.3Hz,2H),4.02(s,2H),3.84 (s,3H),3.66(t,J=5.3Hz,2H),3.65-3.55(m,6H),3.43(dt,J=5.7,4.2Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ:168.98,160.87,159.74,144.55,142.66,140.95,132.19,132.14,131.27 ,130.24,128.74,127.76,126.88,126.38,70.56,69.68,69.44,68.44,63.73,40.07,37.03,34.71.
[0309] Example 40: Synthesis of 1-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-yl)-1-oxo-5,8,11-trioxo-2-azatridecane-13-yl-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetate (compound 40)
[0310]
[0311] Following the synthetic procedure of compound 4, N-Boc-ethylenediamine was replaced by equimolar amounts of (2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate tert-butyl ester, and 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid was replaced by equimolar amounts of 2-(4-oxo-3,4-dihydro-1-oxo-1-phthalazinyl)methyl ester. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 40, a white powder, with an overall yield of 5%. 1H NMR(400MHz,DMSO-d6)δ:12.52(s,1H),9.07(s,1H),9.07(d,J=11.2Hz,1H),8 .78(s,1H),8.09-8.02(m,1H),7.94(dd,J=7.2,1.9Hz,1H),7.79(td,J=7.6,1. 7Hz,1H),7.72(td,J=7.9,1.7Hz,1H),4.22(t,J=5.3Hz,2H),4.02(s,2H),3.84 (s,3H),3.66(t,J=5.3Hz,2H),3.62-3.53(m,6H),3.43(dt,J=5.7,4.2Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ:168.98,160.87,159.74,144.55,142.66,140.95,132.19,132.14,131.27,130.2 4,128.74,127.76,126.88,126.38,70.68,70.55,70.52,69.68,69.44,68.44,63.73,40.07,37.03,34.71.
[0312] Example 41: Synthesis of N-((1R,5S,6S)-3-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetamide (compound 41)
[0313]
[0314] Following the synthetic procedure of compound 4, rel-(1R,5S,6S)-6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 41, a white powder with an overall yield of 15%. 1H NMR(300MHz,DMSO-d6)δ:12.42(s,1H),8.66(s,1H),8.06(dd,J=7.9,1.7Hz,1H) ,7.96-7.89(m,1H),7.79(td,J=7.5,1.7Hz,1H),7.72(td,J=7.9,1.7Hz,1H),7. 16(d,J=7.2Hz,1H),3.86-3.76(m,7H),3.64(dd,J=12.4,2.5Hz,2H),3.26(d,J= 6.8Hz, 1H), 1.85 (tdd, J=6.8, 2.5, 0.8Hz, 1H), 1.71 (tdd, J=6.8, 2.5, 0.8Hz, 1H). 13 C NMR(75MHz,DMSO-d6)δ:171.54,162.19,160.44,148.01,146.17,139.95,132.15,131.4 6,130.55,130.29,129.12,128.74,126.38,125.31,49.33,36.95,34.71,28.55,22.72.
[0315] Example 42: Synthesis of (4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)methyl-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetate (compound 42)
[0316]
[0317] Following the synthetic procedure of compound 4, N-Boc-ethylenediamine was replaced by equimolar amounts of 4-Boc-2-hydroxymethylmorpholine, and 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid was replaced by equimolar amounts of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid. The remaining synthetic raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 42, a white powder with an overall yield of 20%. 1 H NMR(300MHz,DMSO-d6)δ:12.52(s,1H),9.12(s,1H),8.09-8.02(m,1H),7.94(dd,J=7.2,1.9Hz,1H) ,7.84-7.67(m,2H),4.31-4.17(m,4H),4.02(d,J=2.2Hz,2H),3.89-3.71(m,6H),3.75-3.59(m,2H). 13C NMR(75MHz,DMSO-d6)δ:169.08,160.74,159.74,144.55,142.92,140.87,132.36,132.19,131. 72,130.24,128.74,127.76,126.88,126.38,74.00,65.08,65.05,48.80,44.69,37.02,34.71.
[0318] Example 43: Synthesis of N-((4-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)methyl)-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetamide (compound 43)
[0319]
[0320] Following the synthetic procedure of compound 4, 2-aminomethyl-4-Boc-morpholine was used to replace N-Boc-ethylenediamine in equal molar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 43, a white powder with an overall yield of 20%. 1 H NMR(300MHz, DMSO-d6)δ:12.42(s,1H),8.79(s,1H),8.06(dd,J=7.9,1.8Hz,1H),7.96-7.85(m,2H),7.79(td ,J=7.5,1.7Hz,1H),7.72(td,J=7.9,1.7Hz,1H),4.20(p,J=3.5Hz,1H),3.95-3.56(m,9H),3.41-3.21(m,2H). 13 C NMR(75MHz,DMSO-d6)δ:171.01,160.72,159.69,147.68,142.91,140.87,132.40,132.15,131. 72,130.51,128.74,128.35,126.38,125.31,73.74,64.73,48.97,44.76,43.82,37.76,34.71.
[0321] Example 44: Synthesis of N-methyl-N-((1-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperidin-3-yl)methyl)-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetamide (compound 44)
[0322]
[0323] Following the synthetic procedure of compound 4, 1-Boc-3-[(methylamino)methyl]piperidine was used to replace N-Boc-ethylenediamine in equal molar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 44, a white powder with an overall yield of 15%. 1 H NMR (300MHz, DMSO-d6) δ: 12.38 (s, 1H), 8.73 (s, 1H), 8.06 (dd, J = 7.9, 1.7Hz, 1H), 7.9 7-7.90(m,1H),7.79(td,J=7.5,1.7Hz,1H),7.72(td,J=7.9,1.6Hz,1H),3.95(d,J=4. 2Hz,2H),3.84(s,3H),3.75(dd,J=12.4,4.9Hz,1H),3.63-3.53(m,1H),3.49-3.37(m ,2H),3.15(dd,J=5.6,1.2Hz,2H),3.84(s,3H),2.31-2.21(m,1H),1.82-1.50(m,4H). 13 CNMR(75MHz,DMSO-d6)δ:170.59,160.92,159.69,146.37,142.52,140.87,132.15,132.00,131.72,13 0.92,128.74,128.35,126.38,125.31,51.28,48.91,46.58,37.09,34.71,33.98,32.43,27.12,24.12.
[0324] Example 45: Synthesis of 4-(2-(2-(3-methyl-4-oxo-3,4-dihydroimidazol[5,1-d][1,2,3,5]tetraazine-8-carbonyl)-2,8-diazaspiro[4.5]decane-8-yl)-2-oxoethyl)phthalazine-1(2H)-one (compound 45)
[0325]
[0326] Following the synthetic procedure of compound 4, 2,8-diazaspiro[4.5]dec-2-carboxylic acid tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining synthetic raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 45, a white powder with an overall yield of 15%. 1 H NMR(300MHz,DMSO-d6)δ:12.41(s,1H),8.79(s,1H),8.06(dd,J=7.9,1.7Hz, 1H),7.94(dd,J=7.2,1.8Hz,1H),7.79(td,J=7.5,1.7Hz,1H),7.72(td,J=7.9 ,1.7Hz,1H),4.06(s,2H),3.84(s,3H),3.62(d,J=9.3Hz,1H),3.58(ddd,J=6 .9,3.4,1.7Hz,1H),3.58-3.44(m,6H),3.48-3.41(m,1H),1.83-1.65(m,6H). 13 C NMR(75MHz,DMSO-d6)δ:170.14,161.94,159.69,146.39,142.52,140.87,132.15,132.06,131.72, 130.90,128.74,128.35,126.38,125.33,56.34,46.55,42.81,42.46,37.37,37.15,34.71,34.37.
[0327] Example 46: Synthesis of N-((1-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperidin-3-yl)methyl)-2-(4-oxo-3,4-dihydrophthalazine-1-yl)acetamide (compound 46)
[0328]
[0329] Following the synthetic procedure of compound 4, 1-Boc-3-aminomethylpiperidine was used to replace N-Boc-ethylenediamine in equal molar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 46, a white powder with an overall yield of 20%. 1H NMR (300MHz, DMSO-d6) δ: 12.27 (s, 1H), 8.35 (s, 1H), 8.06 (dd, J = 7.9, 1.7Hz, 1H), 7. 96-7.89(m,1H),7.79(td,J=7.5,1.7Hz,1H),7.76-7.64(m,2H),3.95-3.79(m,2H), 3.84(s,3H),3.75(dd,J=12.3,4.6Hz,1H),3.63-3.53(m,1H),3.47-3.36(m,2H),3. 16-3.00(m,2H),2.21(tt,J=6.1,4.7Hz,1H),1.81-1.58(m,3H),1.57-1.44(m,1H). 13 C NMR(75MHz,DMSO-d6)δ:170.91,160.92,159.69,147.68,142.52,140.87,132.15,132.00,131.72, 130.51,128.74,128.35,126.38,125.31,48.65,46.58,44.10,37.74,34.71,34.50,26.78,24.08.
[0330] Example 47: Synthesis of 3-methyl-4-oxo-N-(2-(2-(6-oxo-1,6-dihydropyridazin-3-carbamate)ethoxy)ethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 47)
[0331]
[0332] Following the synthetic procedure of compound 4, [2-(2-aminoethoxy)ethyl]carbamate tert-butyl ester was used to replace N-Boc-ethylenediamine in equimolar amounts, and 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equimolar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 47, a white powder with an overall yield of 15%. 1 H NMR (300MHz, DMSO-d6) δ: 13.14 (s, 1H), 9.07 (s, 1H), 8.78 (s, 1H), 8.25 (t, J = 4.7Hz, 1H), 7.88 (d, J=9.7Hz,1H),6.93(d,J=9.7Hz,1H),3.84(s,3H),3.57(dt,J=6.5,4.3Hz,3H),3.47-3.34(m,5H). 13C NMR (75MHz, DMSO-d6) δ: 166.35, 164.02, 160.87, 142.66, 141.15, 140.95, 133.01, 132.14, 131.27, 123.79, 69.33, 69.12, 40.10, 40.06, 34.71.
[0333] Example 48: Synthesis of 3-methyl-4-oxo-N-(2-(2-(2-(6-oxo-1,6-dihydropyridazine-3-carboxamide)ethoxy)ethoxy)ethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 48)
[0334]
[0335] Following the synthetic procedure of compound 4, 2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 48, a white powder, with an overall yield of 10%. 1 H NMR(300MHz,DMSO-d6)δ:13.14(s,1H),9.07(s,1H),8.78(s,1H),8.25(t,J=4.7Hz,1H),7.8 8(d,J=9.7Hz,1H),6.93(d,J=9.7Hz,1H),3.84(s,3H),3.63-3.55(m,4H),3.47-3.33(m,5H). 13 C NMR(75MHz,DMSO-d6)δ:166.35,164.02,160.87,142.66,141.15,140.95,133. 01,132.14,131.27,123.79,69.65,69.64,69.47,69.25,40.10,40.02,34.71.
[0336] Example 49: Synthesis of 3-methyl-4-oxo-N-(1-oxo-1-(6-oxo-1,6-dihydropyridazin-3-yl)-5,8,11-trioxo-2-azatridecane-13-yl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide (compound 49)
[0337]
[0338] Following the synthetic procedure of compound 4, N-Boc-ethylenediamine was replaced by N-Boc-1,11-diamino-3,6,9-trioxaundecan in equal molar amounts, and 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid was replaced by 6-oxo-1,6-dihydropyridazine-3-carboxylic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 49, a white powder, with an overall yield of 5%. 1 H NMR(400MHz, DMSO-d6)δ:13.14(s,1H),9.07(t,J=5.6Hz,1H),8.78(s,1H),8.25(t,J=4.6Hz,1H),7.88(d,J=9.9Hz,1H ),6.93(d,J=9.9Hz,1H),3.84(s,3H),3.59(dd,J=7.7,4.1Hz,2H),3.43(dt,J=5.5,4.1Hz,2H),3.37(q,J=4.5Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ:166.35,164.02,160.87,142.66,141.15,140.95,133 .01,132.14,131.27,123.79,70.55,69.68,69.47,69.25,40.10,40.02,34.71
[0339] Example 50: Synthesis of 2-(2-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carboxamido)ethoxy)ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (compound 50)
[0340]
[0341] Following the synthetic procedure of compound 4, 2-(2-BOC-aminoethoxy)ethanol was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 50, a white powder, with an overall yield of 15%. 1H NMR(400MHz, DMSO-d6)δ:13.01(s,1H),9.07(t,J=5.6Hz,1H),8.78(s,1H),8.01(d,J=9.9Hz,1H),6 .86(d,J=9.9Hz,1H),4.27(t,J=5.2Hz,3H),3.84(s,3H),3.63(t,J=5.3Hz,3H),3.46-3.41(m,2H). 13 C NMR (100MHz, DMSO-d6) δ: 166.38, 163.52, 160.87, 142.66, 140.95, 138.34, 132.14, 131.27, 123.44, 69.38, 68.53, 64.46, 40.06, 34.71.
[0342] Example 51: Synthesis of 2-(2-(2-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-carboxamido)ethoxy)ethoxy)ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (compound 51)
[0343]
[0344] Following the synthesis procedure of Example 4, tert-butyl 2-(2-(2-(hydroxyethoxy)ethoxy)ethylcarbamate was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as in Example 4, yielding compound 51, a white powder, with an overall yield of 10%. 1 H NMR(400MHz, DMSO-d6)δ:13.01(s,1H),9.07(t,J=5.6Hz,1H),8.78(s,1H),8.01(d,J=9.9Hz,1H),6.8 6(d,J=9.9Hz,1H),4.27(t,J=5.2Hz,2H),3.84(s,3H),3.66-3.56(m,8H),3.43(dt,J=5.5,4.1Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ:166.38,163.53,160.87,142.66,140.95,138.34, 132.14,131.27,123.44,70.56,69.68,69.44,69.17,64.45,40.07,34.71.
[0345] Example 52: Synthesis of 1-(3-methyl-4-oxo-3,4-dihydroimidazolium[5,1-d][1,2,3,5]tetraazine-8-yl)-1-oxo-5,8,11-trioxo-2-azatridecane-13-yl6-oxo-1,6-dihydropyridazine-3-carboxylate (compound 52)
[0346]
[0347] Following the synthetic procedure of compound 4, N-Boc-ethylenediamine was replaced by equimolar amounts of (2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate tert-butyl ester, and 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid was replaced by equimolar amounts of 6-oxo-1,6-dihydropyridazine-3-carboxylic acid. The remaining synthetic raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 52, a white powder, with an overall yield of 5%. 1 H NMR (400MHz, DMSO-d6) δ: 13.01 (s, 1H), 9.07 (t, J = 5.6Hz, 1H), 8.78 (s, 1H), 8.01 (d, J = 9.9Hz, 1H), 6.86 (d, J = 9. 9Hz,1H),4.27(t,J=5.2Hz,2H),3.82(s,3H),3.66-3.57(m,4H),3.60-3.55(m,6H),3.43(dt,J=5.5,4.1Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ:166.38,163.53,160.87,142.66,140.95,138.34,132.14 ,131.27,123.44,70.68,70.55,70.52,69.68,69.44,69.17,64.45,40.07,34.71.
[0348] Example 53: Synthesis of N-((1R,5S,6S)-3-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (compound 53)
[0349]
[0350] Following the synthetic procedure of compound 4, rel-(1R,5S,6S)-6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 53, a white powder with an overall yield of 15%. 1 H NMR(300MHz, DMSO-d6)δ:13.14(s,1H),8.79(s,1H),7.95(d,J=9.7Hz,1H),7.29(d,J=6.6Hz,1H),6.93( d,J=9.7Hz,1H),3.87-3.75(m,5H),3.64(dd,J=12.4,2.5Hz,2H),3.38-3.28(m,1H),1.91-1.71(m,2H). 13 CNMR(75MHz,DMSO-d6)δ:167.70,166.23,162.19,146.17,140.75,139.95,134.15,131.46,130.55,123.64,49.39,34.71,30.18,22.65.
[0351] Example 54: Synthesis of (4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (compound 54)
[0352]
[0353] Following the synthetic procedure of compound 4, N-Boc-ethylenediamine was replaced by an equimolar amount of 4-Boc-2-hydroxymethylmorpholine, and 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid was replaced by an equimolar amount of 6-oxo-1,6-dihydropyridazine-3-carboxylic acid. The remaining synthetic raw materials, reagents, preparation methods, and purification methods were the same as in Example 4, yielding compound 54, which was a white powder with an overall yield of 15%. 1 H NMR(300MHz,DMSO-d6)δ:13.01(s,1H),8.79(s,1H),8.01(d,J=9.9Hz,1H),6.86(d,J=9.9Hz,1H) ,4.34-4.17(m,3H),3.92-3.78(m,1H),3.83-3.71(m,6H),3.76-3.66(m,1H),3.71-3.57(m,1H). 13C NMR(75MHz,DMSO-d6)δ:166.38,163.46,160.74,142.92,140.87,138.50,1 32.36,131.72,131.33,123.44,73.84,65.35,65.05,48.90,44.69,34.71.
[0354] Example 55: Synthesis of N-((4-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)morpholin-2-yl)methyl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (compound 55)
[0355]
[0356] Following the synthetic procedure of compound 4, 2-aminomethyl-4-Boc-morpholine was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 55, which was a white powder with an overall yield of 15%. 1 H NMR (300MHz, DMSO-d6) δ: 13.14 (s, 1H), 8.79 (s, 1H), 8.30 (t, J = 6.0Hz, 1H), 7.88 (d, J = 9.7Hz, 1H), 6.93 (d, J = 9.7Hz ,1H),4.28-4.17(m,1H),3.84(s,3H),3.90-3.76(m,2H),3.81-3.66(m,2H),3.71-3.54(m,2H),3.51-3.34(m,2H). 13 C NMR(75MHz,DMSO-d6)δ:166.35,164.16,160.72,142.91,141.32,140.87,1 33.01,132.40,131.72,123.79,73.55,64.73,49.12,44.76,43.98,34.71.
[0357] Example 56: Synthesis of N-methyl-N-((1-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperidin-3-yl)methyl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (compound 56)
[0358]
[0359] Following the synthetic procedure of compound 4, 1-Boc-3-[(methylamino)methyl]piperidine was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 56, which was a white powder with an overall yield of 15%. 1 H NMR (300MHz, DMSO-d6) δ: 13.23 (s, 1H), 8.79 (s, 1H), 7.92 (d, J = 10.1Hz, 1H), 6.94 (d, J = 10.1Hz, 1H), 3.84 (s, 3H), 3.75 (dd, J = 12.4, 4.9Hz, 1H), 3. 65-3.52(m,1H),3.50-3.35(m,2H),3.33(dd,J=11.6,5.7Hz,1H),3.09(d d,J=11.6,5.7Hz,1H),2.81(s,3H),2.32-2.17(m,1H),1.85-1.48(m,4H). 13 C NMR(75MHz,DMSO-d6)δ:166.36,163.46,160.92,142.52,140.87,137.60,134.32, 132.00,131.72,123.07,51.39,49.00,46.58,37.05,34.71,33.72,27.12,24.12.
[0360] Example 57: Synthesis of 3-methyl-8-(8-(6-oxo-1,6-dihydropyridazine-3-carbonyl)-2,8-diazaspiro[4.5]dec-2-carbonyl)imidazo[5,1-d][1,2,3,5]tetraazine-4(3H)-one (compound 57)
[0361]
[0362] Following the synthetic procedure of compound 4, 2,8-diazaspiro[4.5]dec-2-carboxylic acid tert-butyl ester was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 57, which was a white powder with an overall yield of 15%. 1H NMR(300MHz,DMSO-d6)δ:13.33(s,1H),8.79(s,1H),7.89(d,J=10.2Hz,1H), 6.93(d,J=10.2Hz,1H),3.64-3.55(m,4H),3.52(s,1H),3.53-3.48(m,3H),3 .48(dd,J=12.9,3.3Hz,1H),3.48-3.42(m,1H),1.87(ddd,J=12.5,6.3,3.6H z,3H),1.80(d,J=3.7Hz,1H),1.81-1.75(m,3H),1.68(dd,J=4.8,2.8Hz,1H). 13 C NMR(75MHz,DMSO-d6)δ:166.36,162.88,161.94,142.52,140.87,136.43,134. 06,132.06,131.72,123.20,56.34,46.55,42.49,42.31,37.15,34.71,34.04.
[0363] Example 58: Synthesis of N-((1-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperidin-3-yl)methyl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (compound 58)
[0364]
[0365] Following the synthetic procedure of compound 4, 1-Boc-3-aminomethylpiperidine was used to replace N-Boc-ethylenediamine in equal molar amounts, and 6-oxo-1,6-dihydropyridazine-3-carboxylic acid was used to replace 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoic acid in equal molar amounts. The remaining synthetic raw materials, reagents, preparation methods, and purification methods were the same as those for compound 4, yielding compound 58, which was a white powder with an overall yield of 15%. 1 H NMR(300MHz, DMSO-d6)δ:13.17(s,1H),8.79(s,1H),8.23(s,1H),8.23(d,J=11.6Hz,1H),7.88(d,J=9.7Hz,1H),6.94(d,J=9.7Hz,1H),3.84(s,3H ),3.75(dd,J=12.3,4.6Hz,1H),3.63-3.53(m,1H),3.47-3.36(m,2H),3. 20-3.06(m,2H),2.32-2.19(m,1H),1.81-1.58(m,2H),1.57-1.44(m,1H).13 C NMR(75MHz,DMSO-d6)δ:166.35,164.57,160.92,142.52,141.04,140.87,133. 01,132.00,131.72,123.79,48.44,46.58,44.20,34.71,34.36,26.78,24.08.
[0366] Example 59: Synthesis of 2-((1-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carbonyl)piperidin-3-yl)methyl)-1H-benzo[d]imidazo-4-carboxamide (compound 59)
[0367]
[0368] Following the synthesis procedure of compound 14, 4-BOC-2-morpholinocarboxylic acid was replaced by N-Boc-3-piperidineacetic acid in equal molar amounts. The other raw materials, reagents, preparation methods, and purification methods were the same as those for compound 14, yielding compound 59, which was a pale yellow powder with an overall yield of 20%. 1 H NMR (300MHz, DMSO-d6) δ: 12.09 (s, 1H), 8.79 (s, 1H), 8.19 (s, 2H), 7.88 (dd, J = 8.6, 1. 3Hz,1H),7.51(dd,J=9.0,1.3Hz,1H),7.41(dd,J=9.1,8.4Hz,1H),3.84(s,3H),3.71 (dd,J=12.4,5.3Hz,1H),3.65-3.52(m,1H),3.48-3.36(m,1H),3.31(dd,J=12.5,5.2 Hz,1H),2.88-2.68(m,2H),2.42-2.26(m,1H),1.91-1.75(m,1H),1.80-1.53(m,3H). 13 CNMR(75MHz,DMSO-d6)δ:167.48,160.92,154.97,142.52,140.87,138.12,136.90,132.11, 131.72,126.28,122.91,121.48,116.65,49.59,46.57,34.71,33.55,33.26,28.78,24.22.
[0369] Example 60: Test of the inhibitory activity of the compound against PARP1 enzyme
[0370] Experimental methods:
[0371] (1) Prepare buffer solutions: Prepare 10×PBS phosphate buffer, prepare PBST (10×PBS: pure water: Tween-20 = 100:900:1V / V); prepare 10mM NAD + Prepare 1M DTT (DTT: water = 6.6 mg: 1 mL); prepare 2 mM magnesium chloride solution; prepare 10 μg / μL activated DNA (activated DNA: water = 300 μg: 30 μL); prepare antibody dilution buffer (BSA: PBS = 1 g: 200 mL); prepare PARP buffer (1 M Tris-HCl: NaCl: water = 50 mL: 5.84 mg: 950 mL); prepare reaction buffer (10 mM NAD). + :1M MDTT:2M MgCl2:10μg / μL activated DNA:DMSO:PARP buffer = 15μL:15μL:15μL:15μL:150μL:7.5mL
[0372] (2) Protein coating preparation: Add 100 μL of histone PBS solution (20 μg / mL) to each well of a 96-well microplate, incubate overnight at 4°C (more than 16 h), pour out, wash the plate once with PBST, and wash the plate once with PARP buffer.
[0373] (3) Compound preparation and protein reaction: Weigh the target compound using a 0.01% balance. Prepare a 5mM stock solution using DMSO. Add 0.4μL of the stock solution to 200μL of reaction buffer (diluted 500 times) to obtain a 10μM compound solution. Add 60μL of reaction buffer to the first column of a 96-well plate, and 50μL to each of the remaining wells. Add 15μL of the compound solution (2 replicates) to the first column and mix by pipetting. Add 25μL of the solution to the second column and mix by pipetting. Repeat this process, adding 25μL of the solution to each column until the second to last column. In the last column, set up a negative control group (no compound added, otherwise the same as the positive control group) and a blank control group (no protein added, otherwise the same as the positive control group) with 6 replicates each. Add 50μL of PARP protein (0.2μg / mL, dissolved in PARP buffer) to each well except the blank control group. Incubate at room temperature for 45 minutes. Discard and wash the plate twice with PBST.
[0374] (4) Incubate with primary antibody: Add 100 μL of pADPr antibody (1:1500 V / V) to each well and incubate at room temperature for 1 hour. Pour out the plate and wash twice with PBST.
[0375] (5) Secondary antibody incubation: Add 100 μL of anti-mouse IgG-HRP (1:2000V / V) to each well and incubate at room temperature for 30 minutes. Pour out the plate and wash it 4 times with PBST.
[0376] (6) Color development: Add 100 μL of TMB color development solution to each well and react in the dark for about 15 minutes (observe the color). Then add 50 μL of 2M H2SO4 to each well to stop the reaction. Read the absorbance at 450 nm using a microplate reader.
[0377] Experimental results:
[0378] The half-maximal inhibitory concentrations (IC50) of the compounds against the PARP1 enzyme are shown in Table 1, demonstrating that the representative compounds of this invention can effectively inhibit the activity of PARP1 enzyme.
[0379] Table 1. Half-maximal inhibitory concentrations (IC50) of compounds against PARP1 enzyme 50 )
[0380]
[0381] Note: IC 50 a Data are expressed as the mean ± SD of dose-response curves from three independent experiments. ++++ indicates <1 nM, +++ indicates 1-10 nM, ++ indicates 10-100 nM, + indicates 100-1000 nM, and - indicates >1000 nM.
[0382] Example 61: Test of the inhibitory activity of the compound against the glioblastoma cell line LN229
[0383] PARP1 is closely related to DNA damage repair and can repair the damage caused by temozolomide to tumor cells. Multiple experiments have shown that knocking out PARP1 can improve the therapeutic effect of temozolomide. The inventors further selected representative compounds to investigate their inhibitory activity against the glioblastoma cell line LN229.
[0384] Experimental methods:
[0385] (1) The cells were packed at 5 × 10 3 The cells were seeded at a density of cells / well in 96-well plates and incubated at 37°C and 5% CO2 for 12 hours.
[0386] (2) Discard the culture medium, dissolve the compound in DMSO, dilute it to different concentrations in DMEM medium, add it to a 96-well plate, and continue to incubate under the same conditions for 48 hours.
[0387] (3) Add 15 μL of MTT (5 mg / mL) solution to each well and incubate the 96-well plate at 37 °C for 4 h; discard the supernatant, leaving the blue-purple crystals (formazan) adhering to the bottom of the wells, dissolve them in DMSO, and measure the absorbance at 492 nm using a microplate reader. Aspirate the supernatant and display the absorbance in the microplate reader.
[0388] Experimental results:
[0389] The compounds of this invention all exhibited inhibitory effects on glioblastoma cells. The half-maximal inhibitory concentrations (IC50) of some compounds on glioblastoma cells are shown in Table 2.
[0390] Table 2. Half-maximal inhibitory concentrations (IC50) of the compounds against the LN229 cell line 50 )
[0391]
[0392] Note: IC 50 a Data are expressed as the mean ± SD of the dose-response curves from three parallel experiments. +++ indicates 1-10 μM, ++ indicates 10-100 μM, and + indicates 100-1000 μM.
Claims
1. Temozolomide derivatives or pharmaceutically acceptable salts, crystal forms, or solvates with structures as shown in Formula I: in, R1 is selected from R 2a R 2b R 2c R 2d Each amino group is independently selected from any substituted amino group. 1-8 Alkyl, amino C 1-8 Alkoxy, single or two five- or six-membered alicyclic groups with heteroatoms selected from O, S, and N, single or two five- or six-membered aromatic heterocyclic groups with heteroatoms selected from O, S, and N, bridged cyclic hydrocarbons, N-heterospirocyclic groups, N-alkyl-substituted single or two five- or six-membered alicyclic groups with heteroatoms selected from O, S, and N, and N-alkyl-substituted single or two five- or six-membered aromatic heterocyclic groups with heteroatoms selected from O, S, and N; R 5a R 5b R 5c R 5d Each group is independently selected from hydrogen, hydroxyl, carboxyl, aldehyde, halogen, isopropyl, trifluoromethyl, methoxy, methoxycarbonyl, acetyl, cyano, and nitro. R4 is selected from any substituted amino group C. 1-8 Alkyl, amino C 1-8 Alkoxy, single or two five- or six-membered alicyclic groups with heteroatoms selected from O, S, and N, single or two five- or six-membered aromatic heterocyclic groups with heteroatoms selected from O, S, and N, N-alkyl-substituted single or two five- or six-membered alicyclic groups with heteroatoms selected from O, S, and N, N-alkyl-substituted single or two five- or six-membered aromatic heterocyclic groups with heteroatoms selected from O, S, and N, and methylthioalkylamino; n is 0, 1, 2, or 3; R3 is selected from hydrogen, halogen, methyl, or halogen-substituted methyl; But excluding: R1 is selected from R 2c Selected from m3 = 3, n is 1, and R3 is selected from hydrogen.
2. The temozolomide derivative according to claim 1, characterized in that: R1 is selected from R 2a Selected from R 2b R 2c R 2d Selected independently m1 is an integer from 1 to 4; m2 is 1, 2, or 3; m3 is 1, 2, or 3; R4 is selected from m4 is selected from 1, 2, or 3; n is 1 or 2; R3 is selected from hydrogen and Cl; But excluding: R1 is selected from R 2c Selected from m3 = 3, n is 1, and R3 is selected from hydrogen.
3. The temozolomide derivative according to claim 2, characterized in that: R1 is selected from R 2a Selected from R 2b R 2c Selected independently m2 is 1, 2, or 3; m3 is 1, 2, or 3; R 2d Selected from m1 is 2, 3, or 4; m2 is 1, 2, or 3; m3 is 1, 2, or 3. R4 is selected from m4 is selected from 1, 2, or 3; n is 1 or 2; R3 is selected from hydrogen and Cl; But excluding: R1 is selected from R 2c Selected from m3 = 3, n is 1, and R3 is selected from hydrogen.
4. The temozolomide derivative according to claim 3, characterized in that: R1 is selected from R 2a Selected from R 2b Selected from R 2d Selected from m1 is 2, 3, or 4; m2 is 1, 2, or 3; m3 is 2; n is 1 or 2; R3 is selected from hydrogen and Cl.
5. Temozolomide derivatives or pharmaceutically acceptable salts, crystal forms, or solvates with the following structures:
6. Temozolomide derivatives or pharmaceutically acceptable salts, crystal forms, or solvates with the following structures:
7. A method for preparing the temozolomide derivative according to claim 1, characterized in that: When R1 is selected The synthetic route for temozolomide derivatives is as follows: Among them, R 2a R3, R 5a n is as described in claim 1; Includes the following steps: Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2. Step (ii): Using DMF as the reaction solvent, compound a-1 and compound a-2 react at room temperature for 4 to 26 hours in the presence of HATU and one of DIPEA or TEA. After the reaction is completed, the reaction solution is added to ice water, extracted with ethyl acetate and the ethyl acetate is removed under vacuum. The remaining solid is heated under reflux in acetic acid at 70 to 120 °C for 2 to 6 hours to obtain compound a-3. The molar ratio of compound a-1 to compound a-2 is 1:1 to 1.2:1; the molar ratio of HATU to compound a-2 is 1:1 to 1.5:1; and the molar ratio of one of DIPEA or TEA to compound a-2 is 2:1 to 3:
1. Step (iii): Compound a-3 was reacted at room temperature for 24 h in a mixed solution of THF, MeOH and LiOH aqueous solutions in a volume ratio of 10:3:2 to obtain compound a-4; Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-4 reacts with R... 2a -Boc reacted at room temperature for 4–6 h to give compound a-5; Among them, compound a-4 and R 2a The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound a-4 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound a-4 to acid-binding agent is 1:2 to 1:3; Step (v): Compound a-5 is reacted at room temperature in an acidic reaction system to remove the Boc protecting group, yielding compound a-6; Step (vi): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-6 and compound m-2 are reacted at room temperature for 4-6 hours to obtain the target compound with the structure described in Formula II. The molar ratio of compound a-6 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:
3. R1 is selected from The synthetic route for temozolomide derivatives is as follows: Wherein, R3, R4, and n are as described in claim 1; Includes the following steps: Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2. Step (ii): Using DMF as the reaction solvent, compound a-1 and compound a-7 react at room temperature for 4-6 h in the presence of HATU and one of DIPEA or TEA. After the reaction is completed, the reaction solution is added to ice water, extracted with ethyl acetate and the ethyl acetate is removed under vacuum. The remaining solid is heated in acetic acid at 70-120 °C under reflux for 4-6 h to obtain compound a-8. The molar ratio of compound a-1 to compound a-7 is 1:1 to 1.2:1; the molar ratio of HATU to compound a-7 is 1:1 to 1.5:1; and the molar ratio of one of DIPEA or TEA to compound a-7 is 2:1 to 3:
1. Step (iii): Compound a-8 is reacted at room temperature in an acidic reaction system to remove the Boc protecting group, yielding compound a-9; Step (vii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-9 and compound m-2 are reacted at room temperature for 4-6 hours to obtain the standard compound with the structure shown in Formula III. The molar ratio of compound a-9 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:
3. R1 is selected from The synthetic route for temozolomide derivatives is as follows: Wherein, R3 and n are as described in claim 1; Includes the following steps: Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2. Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound a-1 and compound m-2 were reacted at room temperature for 4-6 h. After the reaction was completed, the reaction solution was added to ice water at a volume ratio of 1:8 to 1:
10. After extraction with ethyl acetate, the ethyl acetate was removed from the organic phase under vacuum. The solid was refluxed in acetic acid at 70-120 °C for 4-6 h. After the reaction was completed, the product was evaporated to dryness and purified by normal-phase silica gel column chromatography to obtain the target compound with the structure shown in Formula IV. The molar ratio of compound a-1 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:1.8 to 1:
3. R1 is selected from The synthetic route for temozolomide derivatives is as follows: Among them, R 2d R3, R 5c R 5d n is as described in claim 1; Includes the following steps: Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2. Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-1 reacts with R... 2d -Boc reacted at room temperature for 4–6 h to give compound b-2; Among them, compound b-1 and R 2d The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound b-1 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound b-1 to acid-binding agent is 1:2 to 1:3; Step (iii): Compound b-2 was reacted in ethyl acetate solution of 4 mol / L hydrochloric acid at room temperature for 2-3 h to remove the Boc protecting group, yielding compound b-3; Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-3 and compound m-2 are reacted at room temperature for 4-6 hours to obtain the target compound with the structure shown in Formula V. The molar ratio of compound b-3 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:
3. R1 is selected from The synthetic route for temozolomide derivatives is as follows: Among them, R 2b R3, R 5b n is as described in claim 1; Includes the following steps: Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2. Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-4 reacts with R... 2b -Boc reacted at room temperature for 4–6 h to give compound b-5; Among them, compound b-4 and R 2b The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound b-4 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound b-4 to acid-binding agent is 1:2 to 1:
3. Step (iii): Compound b-5 was reacted in ethyl acetate solution of 4 mol / L hydrochloric acid at room temperature for 2-3 h to remove the Boc protecting group, yielding compound b-6; Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-6 and compound m-2 are reacted at room temperature for 4 to 6 hours to obtain the target compound with the structure shown in Formula VI. The molar ratio of compound b-6 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:
3. When R1 is selected The synthetic route for temozolomide derivatives is as follows: Among them, R 2c R3 and n are as described in claim 1; Includes the following steps: Step (i): Add compound m-1 to concentrated sulfuric acid, add NaNO2 aqueous solution under ice bath conditions, after the addition is complete, keep in ice bath for 45-60 min, and then react at room temperature for 6-12 h to obtain compound m-2. Step (ii): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-7 reacts with R... 2c -Boc reacted at room temperature for 4–6 h to give compound b-8; Among them, compound b-7 and R 2c The molar ratio of -Boc is 1:1 to 1:1.2; the molar ratio of compound b-7 to amide condensing agent is 1:1 to 1:1.5; the molar ratio of compound b-7 to acid-binding agent is 1:2 to 1:
3. Step (iii): Compound b-8 was reacted in ethyl acetate solution of 4 mol / L hydrochloric acid at room temperature for 2-3 h to remove the Boc protecting group, yielding compound b-9; Step (iv): Using DMF as the reaction solvent, HATU as the amide condensing agent, and DIPEA or TEA as the acid-binding agent, compound b-9 and compound m-2 are reacted at room temperature for 4 to 6 hours to obtain the target compound with the structure shown in Formula VII. The molar ratio of compound b-9 to compound m-2 is 1:1 to 1.2:1; the molar ratio of compound m-2 to amide condensing agent is 1:1 to 1:1.5; and the molar ratio of compound m-2 to acid-binding agent is 1:2 to 1:
3.
8. Use of the temozolomide derivative or pharmaceutically acceptable salt, crystal form, or solvate according to any one of claims 1-6 in the preparation of a PARP1 inhibitor.
9. Use of the temozolomide derivative or pharmaceutically acceptable salt, crystal form, or solvate according to any one of claims 1-6 in the preparation of a medicament for the prevention and / or treatment of tumors; wherein the tumors are glioblastoma, ovarian cancer, breast cancer, bladder cancer, bone cancer, gastric cancer, liver cancer, non-small cell lung cancer, melanoma, prostate cancer, or rectal cancer.
10. A pharmaceutical composition, characterized in that: The pharmaceutical composition comprises, as an active ingredient or main active ingredient, a temozolomide derivative or a pharmaceutically acceptable salt, crystal form or solvate as described in any one of claims 1-5, and formulated into a pharmaceutically acceptable dosage form with a pharmaceutically acceptable carrier.
Citation Information
Cited By
PARP inhibitors - quinoline carboxylic acid coupled derivatives and methods of making and use thereof
CN122127312A
PARP inhibitors - quinoline carboxylic acid coupled derivatives and methods of making and use thereof
CN122127312B
